

Development of oncolytic virotherapy: from genetic modification to combination therapy

Qiaoshuai Lan^{1,*}, Shuai Xia^{1,*}, Qian Wang¹, Wei Xu¹, Haiyan Huang², Shibo Jiang (✉)^{1,3}, Lu Lu (✉)¹

¹Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences and Shanghai Public Health Clinical Center, Fudan University, Shanghai 200032, China; ²Yantai Yuhuangding Hospital, Qingdao University, Yantai 264000, China; ³Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY 10065, USA

© The Author(s) 2020. This article is published with open access at link.springer.com and journal.hep.com.cn

Abstract Oncolytic virotherapy (OVT) is a novel form of immunotherapy using natural or genetically modified viruses to selectively replicate in and kill malignant cells. Many genetically modified oncolytic viruses (OVs) with enhanced tumor targeting, antitumor efficacy, and safety have been generated, and some of which have been assessed in clinical trials. Combining OVT with other immunotherapies can remarkably enhance the antitumor efficacy. In this work, we review the use of wild-type viruses in OVT and the strategies for OV genetic modification. We also review and discuss the combinations of OVT with other immunotherapies.

Keywords immunotherapy; oncolytic virus; genetic modification; immune checkpoint blockade; chimeric antigen receptor T cell

Introduction

Immunotherapy is an important antitumor therapy that involves stimulating or enhancing host antitumor immune response to kill and clear tumor cells [1,2]. Oncolytic virotherapy (OVT) is a new antitumor immunotherapy that uses natural or genetically modified viruses to selectively infect and kill tumor cells [3]. OVT has various advantages over current antitumor therapies. Oncolytic viruses (OVs) can selectively replicate in tumor cells with high safety [4] and carry foreign genes, such as therapeutic and immunostimulatory genes [5] for specific expression at tumor sites [6]. Some OVs can cross the blood–brain barrier (BBB) to kill brain tumor cells, such as reovirus [7] and parvovirus H-1 (H-1PV) [8], and OVs can turn “cold” tumors into “hot” tumors, thereby increasing the cellular sensitivity to other immunotherapies [9,10]. To date, many OVs, including DNA viruses, such as adenovirus (AdV) [11,12], vaccinia virus (VACV) [13,14], herpesvirus

[15,16], and parvovirus [17] and RNA viruses, such as reovirus [18,19], Newcastle disease virus (NDV) [20], and measles virus (MV) [21] (Table 1) have been evaluated for cancer treatment (Fig. 1).

In the last century, scientists found that some viruses, such as NDV [32], MV [33], and parvovirus [34], can naturally kill tumor cells. However, during this period, OVs were derived from wild-type or naturally attenuated virus strains, leaving considerable room for improvement in their safety and antitumor effects [35,36]. In the 1990s, the emergence of recombinant DNA technology accelerated the development of OVT. Genetically modified OVs showed enhanced tumor targeting and killing efficiency against tumor cells with negligible damage to normal cells. The first genetically modified OV was herpes simplex virus (HSV)-1 developed by Martuza *et al.* in 1991 [37,38]. Oncorine (H101), a genetically modified oncolytic adenovirus (OAd), was approved by the State Food and Drug Administration (SFDA, now the National Medical Products Administration (NMPA)) in 2005 for the treatment of nasopharyngeal carcinoma in China [39,40]. Talimogene laherparepvec (T-VEC; brand name Imlygic) was approved by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) for the treatment of advanced melanoma in 2015 [41,42].

Researchers have recently attempted to combine OVT with other antitumor therapies, including chemotherapy

Received November 21, 2019; accepted January 14, 2020

Correspondence: Shibo Jiang, shibojiang@fudan.edu.cn;

Lu Lu, lul@fudan.edu.cn

*These authors contributed equally to this work.




Fig. 1 Schematic of some oncolytic viruses for cancer treatment. Many viruses, including double-stranded DNA viruses, such as AdV, herpes simplex virus (HSV), and VACV; single-stranded DNA viruses, such as parvovirus; negative-sense single-stranded RNA viruses, such as Newcastle disease virus (NDV), measles virus (MV), and vesicular stomatitis virus (VSV); positive-sense single-stranded RNA viruses, such as poliovirus and coxsackievirus; and double-stranded RNA viruses, such as reovirus, have been used in cancer treatment. The terms naked/enveloped are used to describe types of virus; high/moderate/low describes the genomic capacities of OVs.

[43–45], radiotherapy [46,47], small molecules [48,49], and other immunotherapies [50,51], to achieve increased therapeutic effects against tumors. Among these treatments, the combination of OVT with other immunotherapies, especially regimens involving immune checkpoint inhibitors (ICIs) and chimeric antigen receptor-engineered T cell (CAR-T cell) immunotherapies, has shown promise as a cancer treatment [51,52]. OVs can “heat up” tumors, thus enhancing their sensitivity to ICIs [53]. OVs can also piggyback CAR-T cells in a manner that enables them to overcome the immunosuppressive tumor microenvironment (TME) and increase their antitumor activity against solid tumors [54]. Recently, natural OVs have been continuously identified and widely applied in OVT. The renewed development of genetically modified OVs with enhanced tumor-targeting ability, antitumor efficacy, and safety has further promoted the development of OVT. In this work, we review the applications of wild-type viruses and the modifications for improving the tumor-targeting ability, antitumor efficacy, and safety of OVs. We also review and discuss the important research directions for OVT combination with other immunotherapies, including immune checkpoint blockade (ICB) and CAR-T cell therapies.

Wild-type OVs in oncolytic virotherapy

Some wild-type OVs have a natural tropism for tumor cells based on their capacity to recognize highly expressed receptors on tumor cell surfaces or based on abnormal pathways or products in tumor cells, such as a defect in the interferon (IFN) signaling pathway and the activated Ras pathway. Among them, several representative OVs, such as coxsackievirus [55], parvovirus [56], and reovirus [57], have been widely reported.

Coxsackievirus A21 (CVA21) is a promising OV that depends on highly expressed receptor molecules on the surface of tumor cells, intercellular adhesion molecule-1 (ICAM-1, also named CD54), and decay-accelerating factor to preferentially enter, replicate in, and kill tumor cells. CVA21 exhibited antitumor efficacy in multiple cancers, including melanoma, prostate cancer, and multiple myeloma [30]. A CVA21-based OV (CAVATAK[®]) has been assessed in clinical trials for the treatment of malignant melanoma, bladder cancer [58], and uveal melanoma with liver metastases [59]. The results revealed that CAVATAK[®] has a good safety profile and can stimulate systemic antitumor immunity for the treatment of patients with melanoma [60]. CAVATAK[®] can also

Table 1 Characteristics of DNA virus- and RNA virus-derived OV's

Virus type	Virus	Family	Natural host	Receptor	Replication site	Common used virus strain or type	References
DNA virus	Adenovirus	Adenoviridae	Human	CAR, integrin	Nucleus, cytoplasm	Ad5	[22]
	Vaccinia virus	Poxviridae	Human	Unknown	Cytoplasm	Lister, Wyeth, WR	[23]
	Herpesvirus	Herpesviridae	Human	HVEM, nectin	Nucleus, cytoplasm	HSV-1	[24]
	Parvovirus	Parvoviridae	Rat	SARs	Nucleus, cytoplasm	H1-PV	[25]
RNA virus	Measles virus	Paramyxoviridae	Human	CD46, SLAM	Cytoplasm	Edmonston vaccine strain	[26]
	Newcastle disease virus	Paramyxoviridae	Chicken	Unknown	Cytoplasm	HUJ, MTH-68/H	[27]
	Vesicular stomatitis virus	Rhabdoviridae	Pigs, cattle, horses	LDLR	Cytoplasm	Recombinant Indiana strain	[28]
	Poliovirus	Picornaviridae	Human	CD155	Cytoplasm	Sabin vaccine strain	[29]
	Coxsackievirus	Picornaviridae	Human	ICAM-1, DAF	Cytoplasm	CVA21, CVB3	[30]
	Reovirus	Reoviridae	Human	Unknown	Cytoplasm	Reovirus-serotype 3	[31]

CAR, coxsackie adenovirus receptor; HVEM, herpesvirus entry mediator; SARs, sialic acid residues; SLAM, signaling lymphocytic activation molecule; LDLR, low-density lipoprotein receptor; ICAM-1, intercellular adhesion molecule 1; DAF, decay accelerating factor.

induce immune cells to infiltrate the TME, indicating that its use in combination with other antitumor immunotherapies can increase antitumor efficacy.

Wild-type H-1PV exhibits tumor selectivity, mainly depending on tumor-specific abnormal replication and transcription factors and the defective type I IFN-mediated antiviral pathway in tumor cells [17]. H-1PV nonstructural protein 1 (NS1) is important for promoting tumor cell death. Preclinical studies suggested that H-1PV can effectively kill various tumor cells [56], including pancreatic ductal adenocarcinoma cells and glioma cells [61]. In particular, ParvOryx (wild-type H-1PV) showed an excellent safety profile in phase I/IIa clinical trials [8]. Wild-type reovirus can also selectively replicate in tumor cells in association with the abnormally activated Ras pathway in tumor cells [62]. Reovirus can cross the BBB to kill brain tumor cells through intravenous administration [7]. Reolysin® (pelareorep) is a formulation of the reovirus serotype 3 Dearing strain and is being assessed in clinical trials for the treatment of multiple myeloma [63], pancreatic adenocarcinoma [64], and melanoma [65]. Reolysin® has received an orphan drug designation from the US FDA and EMA for the treatment of gastric and pancreatic cancers [31]. In the treatment of multiple myeloma, the single use of Reolysin® did not show obvious antitumor activity [66]. However, when Reolysin® was combined with chemotherapy, such as carboplatin and paclitaxel, it exhibited improved therapeutic efficacy with an objective response rate (ORR) of up to 21% in the treatment of malignant melanoma [19].

Many alphaviruses, such as Semliki Forest virus (SFV) [67,68], Sindbis virus (SINV) [69], and M1, exhibit antitumor activity. M1 is a recently identified Getah-like alphavirus from culicine mosquitoes [70,71]. M1 has tumor selectivity related to zinc-finger antiviral protein (ZAP) deficiency in tumor cells and therefore can selectively replicate in tumor cells and induce apoptosis of the infected tumor cells by inducing irreversible endoplasmic reticulum (ER) stress [72]. M1 showed high tumor cell selectivity and tumor-killing activity during *in vitro* and *in vivo* experiments [73]. Moreover, its antitumor activity can be considerably increased by targeted inhibitors, such as valosin-containing protein (VCP) inhibitor and DNA-dependent kinase (DNA-PK) inhibitor [74,75], suggesting that combining M1 with these inhibitors is an important strategy.

Genetic modifications of OV's

Genetic modification has accelerated the development of OVT [76]. In 1991, the first study reported on a genetically engineered OV, that is, an HSV with thymidine kinase (TK) deletion [38]. Many genetically modified OV's have been evaluated in clinical trials, as shown in Table 2; such OV's include AdV, VACV, and HSV. OV's mainly genetically modified through the deletion of virulence genes to improve the safety and insertion of foreign genes and improve antitumor efficacy or tumor targeting ability of OV's [77]. The genetic modifications of OV's can be

classified into four categories according to purpose: (1) enhancing tumor targeting, (2) improving the safety of OV, (3) increasing antitumor efficacy, and (4) monitoring replication status of OV *in vivo* [78] (Fig. 2).

Enhancing tumor targeting

The tumor tropism of OV is an important feature to ensure that they selectively replicate in and specifically kill tumor cells [79]. Wild-type OV generally depend on tumor-specific cellular receptors or abnormal intracellular pathways and products to enter and selectively replicate in tumor cells and therefore can be optimized through genetic modifications to enhance their tumor targeting. Many genetically engineered OV with enhanced tumor cell targeting ability have been developed on the basis of the tumor-specific high expression of certain receptors and the abnormal intracellular signaling pathways and metabolic status [80].

Engineered tumor tropism targeting specific tumor surface receptors

The nonspecificity, low affinity, or low expression of natural viral receptors on tumor cells can limit the application of wild-type OV. Thus, OV should be genetically modified to increase their binding affinity to specifically expressed receptors on tumor cells and increase their efficiency in entering and targeting tumor cells.

Inserting targeting peptides can improve the entry efficiency of OV [81]. For example, adenovirus type 5 (Ad5) is a widely used OV vector, but its receptor, coxsackie adenovirus receptor (CAR), is not highly expressed in many tumor cells [22]; this phenomenon leads to the low entry efficiency of OAd. Through genetic engineering, an arginine–glycine–aspartic acid (RGD) motif was inserted into the fiber knob domain of Ad5 to generate a newly modified virus, which no longer depends on CAR to enter tumor cells and instead relies on integrins that are highly expressed on tumor cells, to enter tumor cells [82]. Other studies inserted the fiber knob domain derived from adenovirus type 3 (Ad3) into the backbone of Ad5 (also named serotype switching) to allow its entrance to the tumor cells by utilizing the highly expressed Ad3 receptor (desmoglein 2 as the primary receptor) on tumor cells to enter the tumor cells [79]. A similar modification involves inserting the fiber knob domain of adenovirus type 35 (Ad35) into the backbone of Ad5, allowing the OV to utilize the Ad35 receptor (CD46 as the primary receptor) to enter tumor cells [81].

Some envelope glycoproteins (G) from other virus families can be inserted to improve tumor cell targeting.

Betancourt *et al.* [83] reported replacing the G protein of vesicular stomatitis virus (VSV) with human immunodeficiency virus type 1 (HIV-1) gp160 to generate a new OV (VSV-gp160G); this method abandons the natural tissue tropism of VSV and specifically targets the new receptor, CD4. VSV-gp160G does not damage normal CD4 T cells; however, it exhibits potent killing activity against CD4-expressing tumor cells, such as adult T cell leukemia/lymphoma cell lines, in association with defective antiviral immune pathways in these tumor cells. A gene encoding a single-chain antibody (scAb) targeting human epidermal growth factor receptor 2 (HER2) was incorporated into HSV-1, making it fully targeted to tumor cells expressing HER2, and HER2-negative cells were left unharmed [84–86]. This modification also enhanced safety. Insertions of scAb targeting tumor-surface antigens, such as epithelial cell adhesion molecule (EpCAM) [87] and human carcinoembryonic antigen (CEA) [88], have been reported to improve the tumor targeting of OV. Shibata *et al.* [87] reported the insertion of the scAb targeting EpCAM (scEpCAM) into the HSV-1 genome. The engineered virus is highly specific to the EpCAM expressed on the surface of tumor cells to enter tumor cells; it can efficiently and specifically kill tumor cells expressing EpCAM. This strategy can improve the tumor targeting of OV. However, these OV have not yet entered clinical trials, and their clinical efficacy needs to be further confirmed.

Engineered tumor tropism targeting the intracellular abnormalities of tumor cells

The various signaling pathways and the metabolic status of tumor cells are altered compared with those of normal cells [89]. Many features of tumor cells can be utilized by OV to generate tumor selectivity [90]; such features include defective antiviral pathways, such as a defective type I IFN signaling pathway [91]; the loss of expression of tumor suppressor genes, such as loss of the retinoblastoma gene [92]; and elevated signaling pathways, such as a transformed Ras pathway [93]. Therefore, targeting these abnormal pathways or products in tumor cells, deleted virulence factors and inserted tumor-specific promoters or microRNA-targeting sequences (miRNA-TSS) of OV can regulate OV specifically replicating in tumor cells [94,95]. Deletion of virulence factors can improve the safety of OV, which is discussed in the next section on the safety of genetically modified OV. This section introduces the strategies for inserting tumor-specific promoters or miRNA-TSS to improve the tumor targeting of OV.

Insertion of tumor-specific promoters, such as the human telomerase reverse transcriptase (hTERT) promoter [96] and the prostate-specific antigen (PSA) promoter [97], can improve the tumor selectivity of OV [3], which will, in turn, drive the expression of viral genes in tumor cells




Fig. 2 Genetic modifications of OV. (A) Genetic modifications for improving tumor targeting of OV. Entry targeting: serotype switching and insertion of a tumor-targeting peptide, glycoproteins from other viruses, and single-chain antibodies (scAb) targeting tumor-associated antigens can allow OV to target tumor surface molecules and enter tumor cells. Post-entry targeting: insertion of tumor-specific promoters can promote virus replication in tumor cells, while insertion of miRNA target sequences can restrict virus replication in normal cells. (B) Genetic modifications that enhance OV safety. Deletion of virulence genes can reduce the risk of OV infections of normal cells and enhance safety. (C) Genetic modifications to augment the antitumor efficacy of OV. Antitumor efficacy can be augmented by inserting foreign genes, such as genes encoding immunostimulatory molecules/cytokines, suicide genes (pro-apoptotic proteins and prodrug-activating enzymes), extracellular matrix (ECM)-degrading enzymes, and anti-vasculature molecules. (D) Genetic modifications to monitor OV replication. Reporter genes, such as green fluorescent protein (GFP), *Renilla* luciferase (RLuc), sodium-iodide symporter (NIS), and human norepinephrine transporter (NET), can be inserted to monitor OV replication.

Table 2 Oncolytic viruses in clinical trials

Virus	Name of OV's	Genetic modification	Conditions	Phase	NCT Number	Status	References					
HSV	T-VEC	ICP34.5 and ICP47 deletion; GM-CSF insertion	Advanced melanoma Breast cancer Melanoma Melanoma Melanoma	Phase 1 Phase 1/2 Phase 2 Phase 3 Phase 3	NCT03747744 NCT02779855 NCT00289016 NCT01368276 NCT00769704	Recruiting Recruiting Completed Completed Completed; DRR: 36.1% (T-VEC-treated patients) versus 3.8% (GM-CSF treated patients)	[170–172]					
	HSV-1716	ICP34.5 deletion	Glioma	Phase 1	NCT02031965	Terminated						
	G207	ICP34.5 deletion; UL39 disruption	Rhabdomyosarcoma	Phase 1	NCT00931931	Completed						
			Osteosarcoma	Phase 1/2	NCT00028158	Completed						
			Glioma	Phase 1	NCT03911388	Not yet recruiting						
			Brain tumors	Phase 1	NCT02457845	Recruiting						
			Malignant glioma	Phase 1	NCT02062827	Recruiting						
			Glioblastoma multiforme	Phase 1	NCT03259425	Active, not recruiting	[173]					
			Melanoma	Phase 2	NCT02428036	Completed						
			Solid tumors with superficial lesions	Phase 1	NCT03252808	Active, not recruiting						
AdV	LOAd703	CD40L and 4-1BBL insertion; Δ 24 in E1A	Pancreatic cancer	Phase 1	NCT03153085	Completed						
			Melanoma	Phase 2	NCT03225989	Recruiting	[11,156,174]					
			Pancreatic adenocarcinoma	Phase 1/2	NCT02705196	Recruiting						
			Pancreatic cancer	Phase 1/2	NCT02045602	Active, not recruiting						
			Metastatic solid tumor	Phase 1	NCT02045589	Completed						
			Pancreatic adenocarcinoma	Phase 1	NCT03284268	Recruiting						
			Retinoblastoma	Phase 1	NCT03896568	Recruiting						
			Glioblastoma	Phase 1	NCT03178032	Recruiting						
			Brain stem glioma	Phase 1	NCT00805376	Completed; 20% of patients survived > 3 years						
			Brain cancer	Phase 1	NCT02143804	Withdrawn						
CG0070	GM-CSF insertion; E3 deletion	Bladder cancer Bladder cancer	Phase 2	NCT02365818	Completed; overall 47% CR rate at 6 months for all patients and 50% for patients with CIS							
			Phase 2	NCT01598129	Completed							
			Phase 1	NCT03003676	Recruiting							
			ONCOS-102 (CGTG-102)	Type 3 knob and GM-CSF insertion; Δ 24 in E1A	Malignant solid tumor Advanced or unresectable melanoma progressing after PDI blockade	Phase 1	NCT02293850	Recruiting	[175]			
						Phase 1	NCT03190824	Active, not recruiting				
						Phase 1	NCT03921021	Recruiting				
						Phase 2	NCT03213054	Recruiting				
						OBP-301	hTERT promoter insertion	Hepatocellular carcinoma Melanoma	Phase 1	NCT02293850	Recruiting	
									Phase 2	NCT03190824	Active, not recruiting	
						OBP-301	hTERT promoter insertion	Esophagogastric adenocarcinoma Esophageal cancer	Phase 2	NCT03921021	Recruiting	
Phase 1	NCT03213054	Recruiting										

		(Continued)					
Virus	Name of OVs	Genetic modification	Conditions	Phase	NCT Number	Status	References
VACV	JX-594 (Pexa-Vec)	TK deletion; GM-CSF insertion	Melanoma	Phase 1/2	NCT00429312	Completed	[111,148,176,177]
			Ovarian cancer	Phase 2	NCT02017678	Withdrawn	
			Melanoma	Phase 1	NCT00625456	Completed	
			Renal cell carcinoma	Phase 1	NCT03294083	Recruiting	
			Colorectal cancer	Phase 1/2	NCT03206073	Recruiting	
			Hepatocellular carcinoma	Phase 2	NCT00554372	Completed; intrathecal mRECIST	
						Disease control rate at week 8 was 46% overall	
GL-ONC1	Ruc-GFP, β -glucuronidase, and β -galactosidase insertion TK and haemagglutinin disruption	Solid organ cancers	Phase 1	NCT02714374	Active, not recruiting		
		Peritoneal carcinomatosis	Phase 1/2	NCT01443260	Completed; efficient intraperitoneal infection in eight patients (8/9)		
		Cancer of head and neck	Phase 1	NCT01584284	Completed; combinations of GL-ONC1 with radiotherapy and chemotherapy: 1-year (2-year) PFS and OS were 74.4% (64.1%) and 84.6% (69.2%), respectively		
		Advanced cancers (solid tumors)	Phase 1	NCT00794131	Completed		
		Glioblastoma	Phase 1/2	NCT03294486	Recruiting		
		Colon cancer	Phase 1/2	NCT03724071	Recruiting		
		Multiple myeloma	Phase 2	NCT02192775	Recruiting		
		Malignant ovarian tumor	Phase 2	NCT02364713	Recruiting		
		Glioblastoma	Phase 1	NCT00390299	Active, not recruiting		
		Ovarian epithelial cancer or primary peritoneal cancer	Phase 1	NCT00408590	Completed		
VSV	VSV-IFN β -NIS	IFN β and NIS insertion	Malignant solid tumor	Phase 1	NCT02923466	Recruiting	[178]
			Hepatocellular carcinoma	Phase 1	NCT03647163	Recruiting	
			Malignant glioma	Phase 1	NCT03043391	Recruiting	
Poliovirus	PVSRIP0	Replace IRES of poliovirus with IRES from HRV2	Glioblastoma	Phase 1	NCT01491893	Active, not recruiting; OS among the patients who received PVSRIP0 reached a plateau of 21% (95% confidence interval, 11 to 33) at 24 months	[179,180]
			Malignant glioma	Phase 1	NCT01491893	Active, not recruiting; OS among the patients who received PVSRIP0 reached a plateau of 21% (95% confidence interval, 11 to 33) at 24 months	
			Malignant glioma	Phase 1	NCT01491893	Active, not recruiting; OS among the patients who received PVSRIP0 reached a plateau of 21% (95% confidence interval, 11 to 33) at 24 months	
			Malignant glioma	Phase 1	NCT01491893	Active, not recruiting; OS among the patients who received PVSRIP0 reached a plateau of 21% (95% confidence interval, 11 to 33) at 24 months	
			Malignant glioma	Phase 1	NCT01491893	Active, not recruiting; OS among the patients who received PVSRIP0 reached a plateau of 21% (95% confidence interval, 11 to 33) at 24 months	
Maraba virus	MG1-MAGEA3	MAGEA3 insertion	Malignant glioma	Phase 2	NCT02986178	Recruiting	[181]
			Melanoma	Phase 1	NCT03712358	Recruiting	
			Metastatic melanoma	Phase 1	NCT03773744	Not yet recruiting	
			Non-small cell lung cancer	Phase 1/2	NCT02879760	Active, not recruiting	
			HPV-associated cancers	Phase 1	NCT03618953	Active, not recruiting	

(Continued)

Virus	Name of OVs	Genetic modification	Conditions	Phase	NCT Number	Status	References
Coxsackievirus	CAVATAK®	None (wild type)	Uveal melanoma with liver metastases	Phase 1	NCT03408587	Completed	[30]
Reovirus	Pelareorep (Reolysin®)	None (Wild type)	Malignant melanoma	Phase 2	NCT01227551	Completed	[182]
			Malignant glioma	Phase 1	NCT00528684	Completed	
			Osteosarcoma	Phase 2	NCT00503295	Completed	
			Bladder carcinoma	Phase 1	NCT02723838	Withdrawn	
			Pancreatic adenocarcinoma	Phase 1	NCT02620423	Completed	
			Pancreatic adenocarcinoma	Phase 2	NCT01280058	Completed; PFS: 4.9 months (paclitaxel/ carboplatin + pelareorep) versus 5.2 months (paclitaxel/carboplatin)	
Parvovirus H-1	ParvOryx	None (Wild type)	Head and neck cancers	Phase 3	NCT01166542	Completed	[183,184]
			Glioblastoma multiforme	Phase 1/2	NCT01301430	Completed; H-1PV treatment was safe and can extend median survival	
NDV	NDV	None (Wild type)	Pancreatic cancer	Phase 1/2	NCT02653313	Completed	[20,185]
			Glioblastoma	Phase 1/2	NCT01174537	Withdrawn	
			Metastatic cancer	Phase 2	NCT00348842	Withdrawn	

Clinical information from <https://www.clinicaltrials.gov/>. OS, overall survival; PFS, progression-free survival; ORR, objective response rate; mRECIST, modified response evaluation criteria in solid tumors; MAGEA3, melanoma-associated antigen 3; IRES, internal ribosomal entry site; HRV2, human rhinovirus type 2; NIS, sodium/iodide symporter; CEA, carcinoembryonic antigen.

but not in normal cells. As an example, hTERT is highly expressed in most tumor cells but absent in normal cells [98]; hence, the inserted hTERT promoter in OVs can initiate viral gene expression and replication in tumor cells with high hTERT expression [99]. OBP-301, an OAd with an inserted hTERT promoter, can replicate in tumor cells specifically, such as renal cell carcinoma cells and prostate cancer cells [100].

Different from the mechanisms of action of inserted tumor-specific promoters, inserted miRNA-TSs can lead to the viral RNA degradation through miRNAs in normal tissues; therefore, engineered OVs can specifically replicate in tumor cells with low miRNA expression [101,102]. For example, targeting downregulated miRNA-7 in glioblastoma multiforme (GBM), researchers constructed a miRNA-7-sensitive oncolytic MV that specifically infects glioma cells without damaging normal cells [103].

Improving the safety of OVs

The safety of OVs is important for their clinical use. Some natural viruses have the potential to kill tumor cells but can also damage normal cells. Numerous studies have suggested that the deletion of some genes necessary for viral replication in normal cells or virulence genes can improve OV safety in normal cells and maintain their oncolytic capacities; such genes include TK in oncolytic VACV [104,105] and ICP34.5 in oncolytic HSV-1 [106,107].

The viral products encoded by such genes are required for the replication of some OVs in normal cells, and they are abundant in tumor cells. Therefore, OVs can utilize tumor cell products to selectively replicate, but they cannot replicate in normal cells because relevant products are lacking. For example, TK, an important enzyme for nucleotide synthesis, is highly expressed in tumor cells [108] but only expressed at a low level in normal cells. TK encoded by VACV is essential for viral replication in normal cells. The deletion of the TK gene is an important genetic modification of oncolytic VACV [109,110] to improve its safety. Oncolytic VACV with TK deletion can replicate in tumor cells but not in normal cells. Therefore, TK deletion can increase the safety of oncolytic VACV. Some oncolytic VACVs, such as GL-ONC1 and Pexa-Vec (JX-594), currently being assessed in clinical trials have TK deletions. GL-ONC1 has been assessed in clinical trials for the treatment of patients with peritoneal carcinomatosis (phase I/II) or cancer of the head and neck (phase I). Phase I clinical trial of GL-ONC1 for the treatment of peritoneal carcinomatosis [13,111] showed its improved safety but also the emergence of minor adverse events. Phase II clinical trial results for Pexa-Vec showed that it could improve the survival of patients with liver cancer [14]; thus, this OV has now entered phase III clinical trials for the treatment of hepatocellular carcinoma.

Wild-type HSV-1 can cause latent infections in normal neurons, but the deletion of its neurovirulence factor (ICP34.5) can enhance its safety [112]. ICP34.5 antagonizes protein kinase R (PKR)-mediated immune response and is essential for infecting neurons. Oncolytic HSV with ICP34.5 deletion cannot replicate in neurons [24]. Given that PKR is usually downregulated in tumor cells, the virus can replicate normally in these tumor cells. HSV-1716, G207, and T-VEC are oncolytic HSVs with ICP34.5 deletions. T-VEC has been approved by the US FDA for the treatment of melanoma [113]. In a recent study, the ORR among patients with in-transit melanoma metastasis treated with T-VEC was 40.7% [114].

Zika virus (ZIKV) was recently found to have oncolytic properties [115], but ZIKV infections in children can cause serious consequences [116,117]. Wild-type ZIKV could infect glioblastoma stem cells (GSCs; an important target for glioblastoma treatment) and slow down the growth of tumors, but wild-type ZIKV also attacks normal nerve cells [115]; hence, its safety should be further improved. A live-attenuated ZIKV vaccine (ZIKV-LAV) candidate [118] with 10 nucleotide deletions in the 3' untranslated region in the ZIKV genome can maintain its oncolytic activity with increased safety and gene stability [119,120]. In preclinical research, ZIKV-LAV effectively inhibited GSC growth and improved the survival of experimental animals compared with the mock control group. The median survival time of mice transplanted with 387 GSC cells was extended from 30 days to 48 days, while the median survival time of mice transplanted with 4121 GSC cells increased from 31 days to 53 days [119].

Augmenting antitumor efficacy

OVs can kill tumor cells through the following mechanisms: selectively replicating in tumor cells and causing the oncolysis of tumor cells [121]; inducing the immunogenic cell death of tumor cells, thereby releasing damage-associated molecular pattern molecules, tumor-associated antigens, and pathogen-associated molecule patterns that stimulate antitumor immunity to kill other tumor cells [91]; and destroying tumor vasculature to indirectly kill tumor cells [122,123]. Insertion of genes coding for immunostimulatory molecules/cytokines, suicide genes, ECM-degrading enzymes, and anti-vasculature molecules can improve the antitumor efficacy of OVs [76,124,125].

Immunostimulatory molecules/cytokines

OVs induce systemic antitumor immunity, and many cytokines, such as granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin (IL)-12 can increase the antitumor immunity. Thus, many OVs have been armed with immunostimulatory cytokines to improve

their therapeutic efficacy [126]. For example, GM-CSF can recruit antigen-presenting cells (APCs) and promote the presentation of tumor antigens [78]. Various OV_s armed with GM-CSF, including T-VEC (HSV-1), Pexa-Vec (VACV), and CG0070 (AdV), have been evaluated in clinical trials. IL-12 can stimulate IFN- γ production, enhance the effect of T cells, and promote antitumor activity [127]. M032 is an oncolytic HSV expressing IL-12 [128] and is being assessed in the clinical trial for the treatment of GBM (the results of which have not yet been reported). Other cytokines, such as IL-2 [129] and IL-15 [130], can also be inserted to improve antitumor efficiency. However, some secreted cytokines have systemic toxicity [131]. Liu *et al.* [132] have developed a new strategy to solve the side effects of the systemic administration of cytokines. They used membrane-bound IL-2, instead of secretory IL-2, to construct an oncolytic VACV that expresses membrane-bound IL-2 (named vvDD-IL-2-RG). Compared with the oncolytic VACV- expressing secretory IL-2, vvDD-IL-2-RG did not compromise antitumor activity and its toxicity was remarkably reduced.

Inserting other immunostimulatory molecules, such as the costimulatory molecules CD40 ligand (CD40L) and 4-1BB ligand (4-1BBL), has also enhanced the antitumor effects of OV_s [133,134]. CD40 and 4-1BB belong to the tumor necrosis factor receptor (TNFR) superfamily. CD40 and 4-1BBL expressed on the surface of APCs and other cells can recognize and bind CD40L and 4-1BB on the surface of T cells, respectively, enhancing the ability of APCs to present antigens and promote T cell activation [135]. The recombinant adenovirus LOAd703 simultaneously expresses the immunostimulatory molecules CD40L and 4-1BBL [136], resulting in the effective activation of T cells through the CD40 and 4-1BB signaling pathways, respectively; as such, they can enhance antitumor immunity. LOAd703 has entered clinical trials for the treatment of pancreatic cancer [137] but the results have not yet been reported.

Suicide gene

Suicide gene therapy includes two strategies: expressing pro-apoptotic proteins or toxin proteins to kill tumor cells directly and using prodrug-activating systems to kill tumor cells indirectly [138]. Engineered OV_s can express pro-apoptotic proteins or toxin proteins to directly kill tumor cells, such as tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) [139,140] and apoptin [141]. TRAIL can induce the apoptosis of tumor cells but does not damage normal cells [142]. Zhu *et al.* constructed a TRAIL-expressing OAd, which can efficiently kill triple-negative breast cancer cell lines *in vitro* without damaging normal cells and efficiently inhibit the growth of tumors in animal experiments [139]. Similarly, apoptin can induce

the apoptosis of tumor cells but not that of normal cells, and apoptin-expressing OAd can effectively inhibit the growth of gastric carcinoma cells [143].

Conventional chemotherapies lack tumor selectivity and can cause damage to normal cells [144]. By contrast, virus-directed enzyme prodrug therapy is an ideal choice as it involves prodrug-activating enzymes expressed by recombinant OV_s to turn nontoxic prodrugs into toxic drugs to specifically kill tumor cells [145]. TK and cytosine deaminase (CD) are widely used prodrug convertases. Chalikonda *et al.* [146] reported on the oncolytic VACV with an inserted CD gene; CD converts the nontoxic prodrug 5-fluorocytosine (5-FC) into 5-fluorouracil (5-FU) in the tumor sites, substantially enhancing the therapeutic effect owing to the presence of active drugs at the tumor sites. However, some tumor cells are resistant to 5-FU, reducing its therapeutic efficiency [147]. TG6002 is an oncolytic VACV expressing the suicide gene FCU1 [148]. FCU1 is a bifunctional gene comprising FCY1 and FUR1. FCY1 can convert 5-FC into 5-FU, and FUR1 can convert 5-FU into the more potent 5-fluorouracil-monophosphate [149], exerting a strong antitumor effect. The results of clinical trials on TG6002 have yet to be reported.

ECM-degrading enzymes

ECM in tumor tissues can inhibit the intratumoral spread of OV_s and limit their antitumor efficacy [150]. Many studies have explored the effects of ECM-degrading enzymes, such as relaxin [151], matrix metalloproteinase (MMP)-9 [152], chondroitinase ABC [153], and PH20 hyaluronidase [154]; those ECM-degrading enzymes can increase the intratumoral spread of OV_s and improve the antitumor activity of OV_s through degrading ECM components. Therefore, expressing ECM-degrading enzymes is a feasible strategy to increase the antitumor activity of modified OV_s. For example, GLV-1h255, an oncolytic VACV, can express MMP-9 to promote collagen IV degradation [152] and increase the intratumoral spread and antitumor efficacy of OV. VCN-01 is an OAd expressing PH20 hyaluronidase [155], PH20 hyaluronidase can promote the spread of OV_s between tumor cells by degrading the ECM. VCN-01 has now entered clinical trials for the treatment of pancreatic adenocarcinoma and retinoblastoma [156].

Anti-vasculature molecules

Tumor vasculature can transport nutrients and oxygen to tumor cells and is crucial to the growth of tumor cells and an ideal target for antitumor therapy [157]. Previous studies have found that anti-angiogenesis factors expressed by OV_s can effectively inhibit tumor angiogenesis and

enhance the antitumor efficiency of OV. Vascular endothelial growth factor (VEGF) can promote angiogenesis, which is an important target of cancer treatment [158]. Alexa *et al.* constructed an oncolytic VACV expressing scAb-targeting VEGF, and its antitumor efficiency was significantly improved [159]. In addition to targeting VEGF, OVs can express other anti-angiogenic factors, such as endostatin [160,161] and thrombospondin-1 (TSP-1), to destroy tumor blood vessels [162]. Endostatin can inhibit tumor angiogenesis by preventing endothelial cell migration; oncolytic HSV expressing endostatin (HSV-Endo) effectively inhibited tumor angiogenesis and growth in the lung cancer model [160]. TSP-1 can inhibit tumor angiogenesis by inducing apoptosis and can improve the antitumor efficiency of OV; T-TSP-1 is an oncolytic HSV expressing TSP-1 that significantly inhibited the growth of gastric cancer *in vivo* [162].

Monitoring OV replication

Understanding the distribution and replication status of OVs *in vivo* helps in assessing the efficacy and safety of OVs [163]. OV replication can be monitored by incorporating them with reporter genes, such as GFP and Rluc (usually used for optical imaging), NIS, and human norepinephrine transporter (NET) (usually used for deep tissue imaging) [164]. GFP insertion is widely used in OVT, and multiple OVs expressing GFP have been developed, such as MV-GFP (MV) [165], JX-GFP (VACV) [104], and rFMW/GFP (NDV) [166]. With the expression of GFP, fluorescence imaging can be used to directly observe the localization of OVs. However, monitoring OVs or tumors in deep tissues via GFP and Rluc is difficult, whereas NIS or NET can be used to monitor OV replication in deep tissues [164]. NIS is a membrane ion channel that mediates iodine transport. After NIS expressed by OVs takes up the iodide isotope, OV localization can be monitored using single-photon emission computed tomography or positron emission tomography [26,167]. MV-NIS is an oncolytic MV expressing NIS, and it has entered clinical trials for the treatment of multiple myeloma [21].

In addition to the insertion of reporter genes, the replication status of OV *in vivo* can be reflected by the expression of soluble markers [168], such as CEA. MV-CEA is an oncolytic MV expressing CEA; the serum CEA level can reflect the replication status of MV *in vivo* [169], but it cannot be used for localization.

Combination of OVT and other immunotherapies

When OVs are used as monotherapy, their antitumor efficacy can be limited by many factors [186]. Pre-existing

antiviral immunity in human bodies could clear OVs rapidly [187]; the heterogeneity of tumor cells might result in the low efficient replication and spread of OVs [187]; the expression of immune checkpoint molecules might limit the antitumor activity of immune cells, which were attracted into the TME by OVs [51]. Researchers have begun to combine OVT with other antitumor therapies, particularly immunotherapies, including ICB (programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) signaling pathway blockade), and CAR-T cell therapies, to further improve the antitumor efficacy of OVs.

Combinations of OVs and ICB

ICB involves using ICIs to bind to immune checkpoint receptors or ligands and block immune inhibitory signals to treat cancer [188,189]. The PD-1/PD-L1 and CTLA-4 pathways are two important immune inhibitory pathways. Several monoclonal antibodies blocking these two pathways have been approved by the US FDA. The treatment of some tumor types by using ICB is successful [190,191], but many factors that induce resistance of tumor cells to ICB, such as CD8 T cell deficiency in tumor tissues and low expression of immune signal molecules (such as PD-L1), have restricted the antitumor efficacy of ICB [192,193]; many patients also did not benefit from immune checkpoint therapy. Therefore, combinations of OVs with ICB have been widely explored in antitumor research to achieve better outcomes, and some combination therapies have been evaluated in clinical trials (Table 3). The combination of OVs and ICB can exert a synergistic effect. OVs can attract CD8 T cells and natural killer (NK) cells into the TME. This phenomenon addresses the lack of immune cells in the TME and consequent inability of antibodies targeting the PD-1/PD-L1 and CTLA-4 pathways. Anti-PD-1/PD-L1 antibodies can block the PD-L1 induced by OVs (Fig. 3A), and anti-CTLA-4 antibodies can block the corresponding inhibitory signaling pathway and enhance the antitumor activity of immune cells attracted by OVs.

Combinations of OVs and PD-1/PD-L1 blockade

To date, six monoclonal antibodies targeting the PD-1/PD-L1 pathway have been approved by the US FDA for clinical use; among such antibodies, pembrolizumab, nivolumab, and cemiplimab are anti-PD-1 antibodies [209,210], whereas durvalumab, atezolizumab, and avelumab are anti-PD-L1 antibodies [211]. Tumeh *et al.* [212] analyzed samples from patients with melanoma in the phase I clinical trials of pembrolizumab and found that the CD8 T cell density at the tumor site was significantly lower in patients who did not respond to pembrolizumab




Fig. 3 Combinations of oncolytic viruses with immune checkpoint inhibitors and CAR-T cell therapy. (A) Mechanisms of OV combined with ICIs targeting the programmed cell death protein 1 (PD-1)/programmed cell death 1 ligand 1 (PD-L1) pathway. OVs can attract CD8 T cells and NK cells into the TME. The expression of PD-L1 on tumor cells is upregulated by OV infection. Anti-PD-1/PD-L1 antibodies block the PD-1/PD-L1 pathway and stop the immune inhibitory signal. (B) OVs in combination with CAR-T cells in the treatment of solid tumors. Modified OVs can express cytokines that attract CAR-T cells into the TME and enhance their antitumor activities; BiTE-armed OVs express BiTEs that bridge CAR-T cells with tumor cells to prevent the immune evasion of tumor cells; OVs armed with anti-PD1/PD-L1 mini-antibody (mini-body) express anti-PD-1/PD-L1 mini-body blocking the immune inhibitory signal and enhancing the antitumor efficacy of CAR-T cells.

compared with that of patients who responded to pembrolizumab. CD8 T cell deficiency in the TME is an important factor underlying the low efficacy of anti-PD-1 treatment. Studies have reported that OVs can increase the number of CD8 T cells in the TME and peripheral blood [28,213,214], which is helpful in improving the therapeutic effect of PD-1/PD-L1 blockade [189]. OV infections can upregulate PD-L1 expression on the surface of tumor cells [7,194,196,200], while PD-1/PD-L1 blocking antibodies can block the PD-1/PD-L1 signaling pathway. Therefore, combining OVs with PD-1/PD-L1 blockade has synergistic roles in increasing antitumor effects.

Chen *et al.* reported that combining oncolytic HSV-1716 with PD-1 blockade has a pronounced antitumor effect in murine rhabdomyosarcoma models compared with oncolytic HSV-1716 or anti-PD-1 antibody monotherapy; this improvement is associated with an increase in local antitumor T cell immune response [195]. Liu *et al.* combined oncolytic VACV with PD-L1 blocking antibody, which effectively inhibited tumor growth and improved the survival of experimental mice (> 40% experimental mice were cured) [194] in colon cancer and ovarian cancer models. Fend *et al.* reported that combining the WR strain of VACV with ICB effectively improved the survival of experimental animals with MCA205 sarcoma [199]. Samson *et al.* combined oncolytic reovirus with ICB to

treat brain tumors and found that sequential treatment with oncolytic reovirus and PD-1/PD-L1 blocking antibody effectively improved the survival of experimental mice with glioma [7]. Marie-Claude *et al.* also reported that oncolytic Maraba virus can induce long-term antitumor immunity and improve the immunosuppressive status of the TME, enhancing the sensitivity of TNBC to ICB [10]. In the treatment of non-solid tumors, such as acute myeloid leukemia (AML), the combination of OV and PD-1/PD-L1 blockade also produced promising outcomes. Shen *et al.* reported that oncolytic VSV (VSV-IFN β -NIS) combined with anti-PD-L1 antibodies effectively killed murine AML cells and significantly improved the survival of AML-bearing mice [197].

Combinations of OVs and anti-PD-1/PD-L1 antibodies have been assessed in clinical trials. Ribas *et al.* reported the results of a phase Ib clinical trial of intratumoral T-VEC injection combined with pembrolizumab for the treatment of patients with advanced melanoma [200]. T-VEC enhanced the infiltration of CD4 and CD8 T cells and promoted the PD-L1 expression in tumor tissues, thereby improving the efficacy of pembrolizumab that led to an overall response rate of 62% and a complete response rate of 33%. This combination therapy did not increase toxicity compared with pembrolizumab monotherapy. Sun *et al.* reported the results of a clinical trial of T-VEC combined

Table 3 Oncolytic viruses combined with immune checkpoint inhibitors and CAR-T cell therapies

Oncolytic virus	Transgene	ICB/ CAR-T cell	Tumors/tumor cells	Therapeutic outcomes	References
Combinations with ICB in preclinical studies					
vDD-CXCL11 (VACV)	CXCL11	Anti-PD-L1	MC38 colon and ID8 ovarian tumor models	Combination therapy: more than 40% cures in models of colon and ovarian cancers	[194]
HSV1716 (HSV-1)	None	Anti-PD-1	RMS model	Combination therapy significantly prolongs survival of mice bearing M3-9-M tumors	[195]
MV-EGFR, MV-NIS (MV)	EGFR-scAb	Anti-PD-1	GL261 glioma cell	Combination therapy: 60% of mice remained alive for at least 120 days	[196]
Reolysin® (Reovirus)	None	Anti-PD-1	Brain tumor GL261 glioma cell	Combination therapy improves survival	[7]
VSV-mFNβ-NIS (VSV)	mFNβ, NIS	Anti-PD-L1	AML	Combination therapy significantly improves the survival of mice with AML	[197]
MG1 (Maraba virus)	None	Anti-PD-1	Human TNBC cell lines, murine mammary carcinoma	Combination therapy significantly slows tumor growth in the 4T1 model	[10]
NDV-Fluc (NDV)	Fluc	Anti-CTLA-4	MC38 colon carcinoma B16-F10 melanoma	More than 80% protection against tumor re-challenge (combination therapy) vs. 40% (anti-CTLA-4 alone)	[9]
G47-mIL12 (HSV-1)	IL-12	Anti-CTLA-4 and anti-PD-1	Glioma model (CT-2A, 005 GSCs)	Median survival: 66.5 days (triple combination therapy) versus 20 days (mock-treated group)	[198]
WR (VACV)	None	Anti-PD1 or anti-CTLA4	MCA205 tumor	Combination therapy increased survival in MCA205 sarcoma model	[199]
Combinations with ICB in clinical trials					
T-VEC (HSV-1)	GM-CSF	Pembrolizumab	Advanced melanoma	Overall response rate 62%, complete response rate 33%	[200]
T-VEC (HSV-1)	GM-CSF	Pembrolizumab, ipilimumab/nivolumab, or nivolumab	Unresectable stage III-IV melanoma	Overall response rate for on-target lesions: 90% (9/10)	[201]
T-VEC (HSV-1)	GM-CSF	Ipilimumab	Unresectable stage IIIB-IV melanoma	Objective response rate: 50%	[202]
T-VEC (HSV-1)	GM-CSF	Ipilimumab	Advanced melanoma	Objective response rate: 39% (combination therapy) versus 18% (ipilimumab alone)	[203]

Oncolytic virus	Transgene	ICB/ CAR-T cell	Tumors/tumor cells	Therapeutic outcomes	References
Combinations with CAR-T cell therapies					
OAd-BiTE (Adenovirus)	EGFR-targeting-BiTE	CAR-T cell targeting the FR- α	Solid tumors (SKOV3, HCT116, and Panc-1 cell)	Median survival: all animals survived until the experimental endpoint of 41 days (CAR-T cells and OAd-BiTE) versus 20 days (OAd-BiTE alone) or 38 days (CAR-T cells alone)	[204]
OAd-TNF α -IL2 (Adenovirus)	TNF- α and IL-2	Mesothelin-redirected CAR-T cell	Pancreatic cancer (BxPC-3, Capan-2, and AsPC-1 cell line, AsPC-1 tumor xenograft model)	Combination therapy efficiently inhibits tumor growth	[205]
Ad5 Δ 24/Ad5 Δ 24.RANT ES.IL15 (Adenovirus)	RANTES and IL-15	GD2.CAR-T cell	Neuroblastoma cell tumor model	Survival rate: 73% (GD2.CAR-T cells and Ad5 Δ 24.RANTES.IL-15) vs. 44% (GD2.CAR-T cells and Ad5 Δ 24) at day 45	[206]
CAd12_PDL1 (Adenovirus)	PD-L1-antibody, IL-12p70	HER2.CAR-T cell	HNSCC xenograft model	Median survival: more than 100 days (CAd12_PDL1 + CAR-T) vs. 21 or 24 days (control group)	[207]
CAd-VECPDL1 (Adenovirus)	PD-L1 mini-body	HER2.CAR-T cell	Solid tumor cell lines (PC-3, A549, HepG2)	Median survival: 110 days (twofold longer than mice treated with a single agent)	[208]

HSV-1, herpes simplex virus-1; VSV, vesicular stomatitis virus; AML, acute myeloid leukemia; GM-CSF, granulocyte-macrophage colony-stimulating factor; TNBC, triple-negative breast cancer; NDV, Newcastle disease virus; RMS, rhabdomyosarcoma; MV, measles virus; BiTE, bispecific T cell engager; EGFR, epidermal growth factor receptor; FR- α , folate receptor α ; HNSCC, head and neck squamous cell carcinoma; HER2, human epidermal growth factor receptor 2.

with anti-PD-1 antibody for unresectable stage III–IV melanoma treatment, leading to an overall response rate (on-target lesions) of 90% (9/10) [201].

Combinations of OV_s and CTLA-4 blockade

Zamarin *et al.* studied the combination of NDV and CTLA-4 blockade in the syngeneic mouse model [9]. The combination generated a synergistic effect, inhibiting the growth of local tumors. In addition, lymphocyte infiltration induced by NDV increased the sensitivity of distal tumor cells (where no OV was injected) to CTLA-4 blockade. Among the CTLA-4 blocking antibodies, ipilimumab has been approved by the US FDA for the treatment of melanoma [215]. In 2018, the results of the phase II clinical trial of T-VEC combined with ipilimumab for melanoma treatment were reported [203], and phase Ib trial results were reported previously [202]. The combination of the two therapies increased antitumor efficacy compared with ipilimumab alone [203] (ORR: 39% versus 18%) with no reduction in safety.

Comprehensive combination regimens have been used for some tumors with a highly immunosuppressed TME. GBM is one of the most lethal tumors, and its TME is highly immunosuppressed. A standalone ICI may not overcome the immunosuppressive state. Saha *et al.* combined anti-PD-1 antibody, anti-CTLA-4 antibody, and oncolytic HSV expressing IL-12 (G47-mIL-12) for GBM treatment [198]. Compared with dual therapy using anti-PD-1 and anti-CTLA-4 antibodies, triple therapy, including anti-PD-1 antibody, anti-CTLA-4 antibody, and G47-mIL-12, cured most experimental mice with 005 GSC GBM and significantly improved the survival of the CT-2A implanted mice. The median survival of CT-2A implanted mice was 66.5, 20, and 19 days for the triple therapy, mock treatment, and dual antibody therapy, respectively. Triple therapy can effectively trigger immune memory and prevent tumor recurrence compared with dual therapy.

Combinations of OV_s and CAR-T cell therapies

CAR-T cell therapy show considerable promise in cancer treatment. This therapy involves CAR-T cells derived from patients' T cells with an additional insertion of the chimeric antigen receptor (CAR) gene to enhance tumor cell recognition [216]. CAR-T cells targeting CD19 is the first CAR-T cell therapy approved by the US FDA for the treatment of B cell lymphoma [217]. CAR consists of an extracellular antigen recognition domain, a transmembrane region, and an intracellular signal domain [218]. The antigen recognition domain is an antibody fragment that recognizes targeted antigens. The intracellular signaling domain stimulates T cell activation and proliferation to kill target cells [219]. CAR-T cell therapies are successful in the treatment of several hematopoietic malignancies

[220,221] but not in the treatment of solid tumors [222]; the immunosuppressive TME is a major obstacle to the role of CAR-T cells [223]. Given the many types of immunosuppressive cells, such as regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs) in the TME [224], and the lack of chemokines to attract tumor-specific T cells, the therapeutic efficacy of CAR-T cell therapy in solid tumors is limited [222].

Combining CAR-T cell therapy with genetically modified OV_s can significantly increase CAR-T cell infiltration into the TME and enhance the therapeutic effect of CAR-T cells in solid tumors, as shown in Fig. 3B. Those modified OV_s can attract CAR-T cells to the TME via cytokine expression. Nishio *et al.* inserted the genes encoding a chemokine (RANTES) and a cytokine (IL-15) into OAd to create Ad5Δ24.RANTES.IL-15. The intratumoral injection of Ad5Δ24.RANTES.IL-15 increased the infiltration of CAR-T cells targeting the tumor antigen GD2 (GD2. CAR-T cells) into the TME, thereby enhancing their tumor-killing ability [206]. Watanabe *et al.* constructed an AdV expressing TNF- α and IL-2 (OAd-TNF α -IL2) and proved that it could enhance the function of CAR-T cells [205].

Bispecific T cell engager (BiTE) is a fusion protein composed of two scAb fragments; one targets specific molecules on the surface of tumor cells, and the other binds to CD3 ϵ on the surface of T cells [225]. BiTE can bridge T cells and tumor cells, thereby promoting T cell activation to kill tumor cells [226]. Blinatumomab (BiTE targeting CD19) has been approved by the US FDA for the treatment of B cell acute lymphoblastic leukemia [227]. The combination of OV expressing BiTE with CAR-T cells can also produce potent antitumor activity [228]. Folate receptor α (FR- α), highly expressed in ovarian, breast, and lung tumor cells, is an important target for antitumor therapy [229]. However, small partial tumor cells remain with low or even no expression of FR- α in those tumor lesions that can lead to immune escape. Wing *et al.* [204] constructed an OAd armed with BiTE targeting epidermal growth factor receptor (OAd-BiTE). In the combination of OAd-BiTE and anti-FR- α CAR-T cells, EGFR-targeting BiTE expressed by OAd bridged the EGFR-overexpressing tumor cells and CAR-T cells to promote CAR-T cell activation and proliferation, and their ability to kill tumor cells was enhanced; as such, the survival of experimental mice was prolonged. All mice treated with CAR-T cells plus OAd-BiTE survived up to the experimental endpoint of 41 days, whereas the median survival of OAd-BiTE-only mice was 20 days and that of CAR-T cells-only mice was 38 days.

Immune inhibitory molecules on the surface of cancer cells also affect the efficiency of CAR-T cell therapy. The transduction of immune checkpoint signals may decrease the therapeutic efficiency of CAR-T cells [230,231], while combinations of ICIs and CAR-T cells can increase the

antitumor effects of CAR-T cells [232,233]. Tanoue *et al.* used an OAd expressing anti-PD-L1 mini-antibody (CAD-VECPDL1) to block the transduction of the PD-1/PD-L1 inhibitory signaling pathway and improve the antitumor effect of CAR-T cells; the median survival of mice treated with CAD-VECPDL1 and HER2.CAR-T cells was 110 days, which is twofold longer than that of mice treated with single agent of OAd or CAR-T cells [208]. Compared with the systemic injection of anti-PD-L1 antibody, the anti-PD-L1 mini-antibody (mini-body) produced by OVVs mainly localized in the tumor tissue with fewer adverse events [234]. Shaw *et al.* constructed an OAd expressing anti-PD-L1 mini-body and cytokine IL-12p70 (CAD12_PDL1) [207]. IL-12p70 expression could further promote CAR expression and enhance the tumor-killing effect. In the head and neck squamous cell carcinoma (HNSCC) xenograft model, combining CAD12_PDL1 and CAR-T cell therapy improved the median survival time of experimental animals by > 100 days in the CAD12_PDL1 + CAR-T group versus 21 or 24 days in the untreated group. At present, combinations of OVVs and CAR-T cells for cancer treatment are still at the preclinical stage and have not yet entered clinical trials (Table 3).

Conclusions and future prospects

With its development for more than 100 years, OVT has become highly efficient for cancer treatment [3]. OVVs can specifically infect and kill tumor cells, remodel the immunosuppressive TME, and stimulate the systemic antitumor response. New viruses with oncolytic potential, such as M1 [75] and ZIKV [115,119], have been continuously discovered, thus further enriching OVT. Genetic modification can improve the safety and antitumor efficacy of OVVs, which can be designed to carry different foreign genes to kill different kinds of tumor cells. T-VEC has been approved by the US FDA and EMA for the treatment of melanoma [41]. Some OVVs, such as Pexa-Vec and Reolysin®, are being assessed in phase III clinical trials.

The combination of OVT with ICB or CAR-T cell therapies can have synergistic effects, which might play an important role in clinical cancer treatment in the future. OVVs can be also combined with other immunotherapies, such as tumor-infiltrating lymphocyte (TIL) therapies [235]. In TIL therapies, patients usually need to be injected with IL-2 to promote TIL proliferation, which might cause many adverse events [236]. The toxicity caused by systematic injections of high-dose IL-2 can be avoided by the intratumoral injection of OAd expressing IL-2 [237]. OVVs combined with tumor-targeted monoclonal antibodies, such as trastuzumab [238] and bevacizumab [239] and some small-molecule antitumor compounds, such as trametinib [240] and NU7441 [75], can generate

synergistic effects and thus have broad applications in cancer treatment.

However, some shortcomings or problems still confound the full use of OVT. For example, the small genomic capacities of some OVVs, such as coxsackievirus and reovirus, limit their ability to accommodate large foreign genes that can optimize their antitumor efficacy [79]. Genetic modification by deleting virulence genes to improve the safety of OVVs also reduces the antitumor efficacy of OVVs [241]. Although encouraging results and broad applications have been achieved with the combination of OVT and other antitumor immunotherapies, further studies on the combination therapy schedules, including dosages, injection routes, and times, should be conducted to obtain the best antitumor efficiency.

Acknowledgements

This work was supported by grants from the National Megaprojects of China for Major Infectious Diseases (No. 2018ZX10301403 to LL), the National Natural Science Foundation of China (Nos. 81661128041, 81672019, and 81822045 to LL; No. 81630090 to SJ; No. 81701998 to QW and No. 81703571 to WX), China Postdoctoral Science Foundation (Nos. 2018M640341 and 2019T120302 to SX), and the Sanming Project of Medicine in Shenzhen (to SJ).

Compliance with ethics guidelines

Qiaoshuai Lan, Shuai Xia, Qian Wang, Wei Xu, Haiyan Huang, Shibo Jiang, and Lu Lu declare no conflict of interest. This manuscript is a review article and does not involve a research protocol requiring approval by relevant institutional review board or ethics committee.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.

The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

To view a copy of this licence, visit <https://creativecommons.org/licenses/by/4.0/>.

References

1. Khalil DN, Smith EL, Brentjens RJ, Wolchok JD. The future of

- cancer treatment: immunomodulation, CARs and combination immunotherapy. *Nat Rev Clin Oncol* 2016; 13(5): 273–290
2. Yang Y. Cancer immunotherapy: harnessing the immune system to battle cancer. *J Clin Invest* 2015; 125(9): 3335–3337
 3. Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. *Nat Rev Drug Discov* 2015; 14(9): 642–662
 4. Chiocca EA, Rabkin SD. Oncolytic viruses and their application to cancer immunotherapy. *Cancer Immunol Res* 2014; 2(4): 295–300
 5. Yu F, Wang X, Guo ZS, Bartlett DL, Gottschalk SM, Song XT. T-cell engager-armed oncolytic vaccinia virus significantly enhances antitumor therapy. *Mol Ther* 2014; 22(1): 102–111
 6. Wang P, Li X, Wang J, Gao D, Li Y, Li H, Chu Y, Zhang Z, Liu H, Jiang G, Cheng Z, Wang S, Dong J, Feng B, Chard LS, Lemoine NR, Wang Y. Re-designing interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent. *Nat Commun* 2017; 8(1): 1395
 7. Samson A, Scott KJ, Taggart D, West EJ, Wilson E, Nuovo GJ, Thomson S, Combs R, Mathew RK, Fuller MJ, Kottke TJ, Thompson JM, Ilett EJ, Cockle JV, van Hille P, Sivakumar G, Polson ES, Turnbull SJ, Appleton ES, Migneco G, Rose AS, Coffey MC, Beirne DA, Collinson FJ, Ralph C, Alan Anthony D, Twelves CJ, Furness AJ, Quezada SA, Wurdak H, Errington-Mais F, Pandha H, Harrington KJ, Selby PJ, Vile RG, Griffin SD, Stead LF, Short SC, Melcher AA. Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade. *Sci Transl Med* 2018; 10(422): eaam7577
 8. Geletneky K, Hajda J, Angelova AL, Leuchs B, Capper D, Bartsch AJ, Neumann J-O, Schönning T, Hüsing J, Beelte B, Kiprianova I, Roscher M, Bhat R, von Deimling A, Brück W, Just A, Frehtman V, Löbhard S, Terletskaia-Ladwig E, Fry J, Jochims K, Daniel V, Krebs O, Dahm M, Huber B, Unterberg A, Rommelaere J. Oncolytic H-1 parvovirus shows safety and signs of immunogenic activity in a first phase I/IIa glioblastoma trial. *Mol Ther* 2017; 25(12): 2620–2634
 9. Zamarin D, Holmgaard RB, Subudhi SK, Park JS, Mansour M, Palese P, Merghoub T, Wolchok JD, Allison JP. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. *Sci Transl Med* 2014; 6(226): 226ra32
 10. Bourgeois-Daigneault MC, Roy DG, Aitken AS, El Sayes N, Martin NT, Varette O, Falls T, St-Germain LE, Pelin A, Lichty BD, Stojdl DF, Ungerechts G, Diallo JS, Bell JC. Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy. *Sci Transl Med* 2018; 10(422): eaao1641
 11. Lang FF, Conrad C, Gomez-Manzano C, Yung WKA, Sawaya R, Weinberg JS, Prabhu SS, Rao G, Fuller GN, Aldape KD, Gumin J, Vence LM, Wistuba I, Rodriguez-Canales J, Villalobos PA, Dirven CMF, Tejada S, Valle RD, Alonso MM, Ewald B, Peterkin JJ, Tufaro F, Fueyo J. Phase I study of DNX-2401 (Delta-24-RGD) oncolytic adenovirus: replication and immunotherapeutic effects in recurrent malignant glioma. *J Clin Oncol* 2018; 36(14): 1419–1427
 12. Packiam VT, Lamm DL, Barocas DA, Trainer A, Fand B, Davis RL 3rd, Clark W, Kroeger M, Dumbadze I, Chamie K, Kader AK, Curran D, Gutheil J, Kuan A, Yeung AW, Steinberg GD. An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: interim results. *Urol Oncol* 2018; 36(10): 440–447
 13. Mell LK, Brumund KT, Daniels GA, Advani SJ, Zakeri K, Wright ME, Onyeama SJ, Weisman RA, Sanghvi PR, Martin PJ, Szalay AA. Phase I trial of intravenous oncolytic vaccinia virus (GL-ONC1) with cisplatin and radiotherapy in patients with locoregionally advanced head and neck carcinoma. *Clin Cancer Res* 2017; 23(19): 5696–5702
 14. Heo J, Reid T, Ruo L, Breitbart CJ, Rose S, Bloomston M, Cho M, Lim HY, Chung HC, Kim CW, Burke J, Lencioni R, Hickman T, Moon A, Lee YS, Kim MK, Daneshmand M, Dubois K, Longpre L, Ngo M, Rooney C, Bell JC, Rhee BG, Patt R, Hwang TH, Kim DH. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. *Nat Med* 2013; 19(3): 329–336
 15. Kaufman HL, Bines SD. OPTIM trial: a phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma. *Future Oncol* 2010; 6(6): 941–949
 16. Kasuya H, Kodera Y, Nakao A, Yamamura K, Gewen T, Zhiwen W, Hotta Y, Yamada S, Fujii T, Fukuda S, Tsurumaru N, Kuwahara T, Kikumori T, Koide Y, Fujimoto Y, Nakashima T, Hirooka Y, Shiku H, Tanaka M, Takesako K, Kondo T, Aleksic B, Kawashima H, Goto H, Nishiyama Y. Phase I dose-escalation clinical trial of HF10 oncolytic herpes virus in 17 Japanese patients with advanced cancer. *Hepatogastroenterology* 2014; 61(131): 599–605
 17. Nüesch JP, Lacroix J, Marchini A, Rommelaere J. Molecular pathways: rodent parvoviruses—mechanisms of oncolysis and prospects for clinical cancer treatment. *Clin Cancer Res* 2012; 18(13): 3516–3523
 18. Noonan AM, Farren MR, Geyer SM, Huang Y, Tahiri S, Ahn D, Mikhail S, Ciombor KK, Pant S, Aparo S, Sexton J, Marshall JL, Mace TA, Wu CS, El-Rayes B, Timmers CD, Zwiebel J, Lesinski GB, Villalona-Calero MA, Bekaii-Saab TS. Randomized phase 2 trial of the oncolytic virus Pelareorep (Reolysin) in upfront treatment of metastatic pancreatic adenocarcinoma. *Mol Ther* 2016; 24(6): 1150–1158
 19. Mahalingam D, Fountzilias C, Moseley J, Noronha N, Tran H, Chakrabarty R, Selvaggi G, Coffey M, Thompson B, Sarantopoulos J. A phase II study of REOLYSIN® (pelareorep) in combination with carboplatin and paclitaxel for patients with advanced malignant melanoma. *Cancer Chemother Pharmacol* 2017; 79(4): 697–703
 20. Tayeb S, Zakay-Rones Z, Panet A. Therapeutic potential of oncolytic Newcastle disease virus: a critical review. *Oncolytic Virother* 2015; 4: 49–62
 21. Dispenzieri A, Tong C, LaPlant B, Lacy MQ, Laumann K, Dingli D, Zhou Y, Federspiel MJ, Gertz MA, Hayman S, Buadi F, O'Connor M, Lowe VJ, Peng KW, Russell SJ. Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma. *Leukemia* 2017; 31(12): 2791–2798
 22. Niemann J, Kühnel F. Oncolytic viruses: adenoviruses. *Virus Genes* 2017; 53(5): 700–706
 23. Torres-Domínguez LE, McFadden G. Poxvirus oncolytic virotherapy. *Expert Opin Biol Ther* 2019; 19(6): 561–573

24. Watanabe D, Goshima F. Oncolytic virotherapy by HSV. *Adv Exp Med Biol* 2018; 1045: 63–84
25. Angelova AL, Barf M, Geletneky K, Unterberg A, Rommelaere J. Immunotherapeutic potential of oncolytic H-1 parvovirus: hints of glioblastoma microenvironment conversion towards immunogenicity. *Viruses* 2017; 9(12): 382
26. Msaouel P, Opyrchal M, Dispenzieri A, Peng KW, Federspiel MJ, Russell SJ, Galanis E. Clinical trials with oncolytic measles virus: current status and future prospects. *Curr Cancer Drug Targets* 2018; 18(2): 177–187
27. Schirmmacher V. Fifty years of clinical application of Newcastle disease virus: time to celebrate! *Biomedicines* 2016; 4(3): 16
28. Durham NM, Mulgrew K, McGlinchey K, Monks NR, Ji H, Herbst R, Suzich J, Hammond SA, Kelly EJ. Oncolytic VSV primes differential responses to immuno-oncology therapy. *Mol Ther* 2017; 25(8): 1917–1932
29. Brown MC, Dobrikova EY, Dobrikov MI, Walton RW, Gemberling SL, Nair SK, Desjardins A, Sampson JH, Friedman HS, Friedman AH, Tyler DS, Bigner DD, Gromeier M. Oncolytic polio virotherapy of cancer. *Cancer* 2014; 120(21): 3277–3286
30. Bradley S, Jakes AD, Harrington K, Pandha H, Melcher A, Errington-Mais F. Applications of coxsackievirus A21 in oncology. *Oncolytic Virother* 2014; 3: 47–55
31. Bourhill T, Mori Y, Rancourt DE, Shmulevitz M, Johnston RN. Going (Reo)Viral: factors promoting successful reoviral oncolytic infection. *Viruses* 2018; 10(8): 421
32. Wheelock EF, Dingle JH. Observations on the repeated administration of viruses to a patient with acute leukemia. A preliminary report. *N Engl J Med* 1964; 271(13): 645–651
33. Zygiert Z. Hodgkin's disease: remissions after measles. *Lancet* 1971; 297(7699): 593
34. Toolan HW, Saunders EL, Southam CM, Moore AE, Levin AG. H-1 virus viremia in the human. *Proc Soc Exp Biol Med* 1965; 119(3): 711–715
35. Howells A, Marelli G, Lemoine NR, Wang Y. Oncolytic viruses—interaction of virus and tumor cells in the battle to eliminate cancer. *Front Oncol* 2017; 7(195): 195
36. Aghi M, Martuza RL. Oncolytic viral therapies—the clinical experience. *Oncogene* 2005; 24(52): 7802–7816
37. Eissa IR, Bustos-Villalobos I, Ichinose T, Matsumura S, Naoe Y, Miyajima N, Morimoto D, Mukoyama N, Zhiwen W, Tanaka M, Hasegawa H, Sumigama S, Aleksic B, Kodera Y, Kasuya H. The current status and future prospects of oncolytic viruses in clinical trials against melanoma, glioma, pancreatic, and breast cancers. *Cancers (Basel)* 2018; 10(10): 356
38. Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM. Experimental therapy of human glioma by means of a genetically engineered virus mutant. *Science* 1991; 252(5007): 854–856
39. Liang M. Oncorine, the world first oncolytic virus medicine and its update in China. *Curr Cancer Drug Targets* 2018; 18(2): 171–176
40. Wei D, Xu J, Liu XY, Chen ZN, Bian H. Fighting cancer with viruses: oncolytic virus therapy in China. *Hum Gene Ther* 2018; 29(2): 151–159
41. Kohlhapp FJ, Zloza A, Kaufman HL. Talimogene laherparepvec (T-VEC) as cancer immunotherapy. *Drugs Today (Barc)* 2015; 51(9): 549–558
42. Conry RM, Westbrook B, McKee S, Norwood TG. Talimogene laherparepvec: first in class oncolytic virotherapy. *Hum Vaccin Immunother* 2018; 14(4): 839–846
43. Bourgeois-Daigneault MC, St-Germain LE, Roy DG, Pelin A, Aitken AS, Arulanandam R, Falls T, Garcia V, Diallo JS, Bell JC. Combination of paclitaxel and MG1 oncolytic virus as a successful strategy for breast cancer treatment. *Breast Cancer Res* 2016; 18(1): 83
44. Garofalo M, Saari H, Somersalo P, Crescenti D, Kuryk L, Aksela L, Capasso C, Madetoja M, Koskinen K, Oksanen T, Mäkitie A, Jalasvuori M, Cerullo V, Ciana P, Yliperttula M. Antitumor effect of oncolytic virus and paclitaxel encapsulated in extracellular vesicles for lung cancer treatment. *J Control Release* 2018; 283: 223–234
45. Binz E, Berchtold S, Beil J, Schell M, Geisler C, Smirnow I, Lauer UM. Chemovirotherapy of pancreatic adenocarcinoma by combining oncolytic vaccinia virus GLV-1h68 with *nab*-paclitaxel plus gemcitabine. *Mol Ther Oncolytics* 2017; 6: 10–21
46. Wilkinson MJ, Smith HG, McEntee G, Kyula-Currie J, Pencavel TD, Mansfield DC, Khan AA, Roulstone V, Hayes AJ, Harrington KJ. Oncolytic vaccinia virus combined with radiotherapy induces apoptotic cell death in sarcoma cells by down-regulating the inhibitors of apoptosis. *Oncotarget* 2016; 7(49): 81208–81222
47. O'Cathail SM, Pokrovska TD, Maughan TS, Fisher KD, Seymour LW, Hawkins MA. Combining oncolytic adenovirus with radiation—a paradigm for the future of radiosensitization. *Front Oncol* 2017; 7: 153
48. McKenzie BA, Zemp FJ, Pisklakova A, Narendran A, McFadden G, Lun X, Kenchappa RS, Kurz EU, Forsyth PA. *In vitro* screen of a small molecule inhibitor drug library identifies multiple compounds that synergize with oncolytic myxoma virus against human brain tumor-initiating cells. *Neuro-oncol* 2015; 17(8): 1086–1094
49. Dornan MH, Krishnan R, Macklin AM, Selman M, El Sayes N, Son HH, Davis C, Chen A, Keillor K, Le PJ, Moi C, Ou P, Pardin C, Canez CR, Le Boeuf F, Bell JC, Smith JC, Diallo JS, Boddy CN. First-in-class small molecule potentiators of cancer virotherapy. *Sci Rep* 2016; 6(1): 26786
50. Ajina A, Maher J. Prospects for combined use of oncolytic viruses and CAR T-cells. *J Immunother Cancer* 2017; 5(1): 90
51. Chen CY, Hutzen B, Wedekind MF, Cripe TP. Oncolytic virus and PD-1/PD-L1 blockade combination therapy. *Oncolytic Virother* 2018; 7: 65–77
52. Russell L, Peng KW, Russell SJ, Diaz RM. Oncolytic viruses: priming time for cancer immunotherapy. *BioDrugs* 2019; 33(5): 485–501
53. Kelly KR, Espitia CM, Zhao W, Wu K, Visconte V, Anwer F, Calton CM, Carew JS, Nawrocki ST. Oncolytic reovirus sensitizes multiple myeloma cells to anti-PD-L1 therapy. *Leukemia* 2018; 32(1): 230–233
54. Achard C, Surendran A, Wedge ME, Ungerechts G, Bell J, Ilkow CS. Lighting a fire in the tumor microenvironment using oncolytic immunotherapy. *EBioMedicine* 2018; 31: 17–24
55. Au GG, Lincz LF, Enno A, Shafren DR. Oncolytic coxsackievirus A21 as a novel therapy for multiple myeloma. *Br J Haematol* 2007; 137(2): 133–141
56. Geiss C, Kis Z, Leuchs B, Frank-Stöhr M, Schlehofer JR, Rommelaere J, Dinsart C, Lacroix J. Preclinical testing of an

- oncolytic parvovirus: standard protoparvovirus H-1PV efficiently induces osteosarcoma cell lysis *in vitro*. *Viruses* 2017; 9(10): 301
57. Vidal L, Pandha HS, Yap TA, White CL, Twigger K, Vile RG, Melcher A, Coffey M, Harrington KJ, DeBono JS. A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer. *Clin Cancer Res* 2008; 14(21): 7127–7137
 58. Annels NE, Mansfield D, Arif M, Ballesteros-Merino C, Simpson GR, Denyer M, Sandhu SS, Melcher AA, Harrington KJ, Davies B, Au G, Grose M, Bagwan I, Fox B, Vile R, Mostafid H, Shafren D, Pandha HS. Phase I trial of an ICAM-1-targeted immunotherapeutic-coxsackievirus A21 (CVA21) as an oncolytic agent against non muscle-invasive bladder cancer. *Clin Cancer Res* 2019; 25(19): 5818–5831
 59. Annels NE, Mansfield D, Arif M, Ballesteros-Merino C, Simpson GR, Denyer M, Sandhu SS, Melcher AA, Harrington KJ, Davies B, Au G, Grose M, Bagwan I, Fox B, Vile R, Mostafid H, Shafren D, Pandha HS. Viral targeting of non-muscle-invasive bladder cancer and priming of antitumor immunity following intravesical coxsackievirus A21. *Clin Cancer Res* 2019 Aug 14. [Epub ahead of print] doi: 10.1158/1078-0432.CCR-18-4022
 60. Andtbacka RHI, Curti BD, Kaufman H, Daniels GA, Nemunaitis JJ, Spitler LE, Hallmeyer S, Lutzky J, Schultz SM, Whitman ED, Zhou K, Karpathy R, Weisberg JI, Grose M, Shafren D. Final data from CALM: a phase II study of coxsackievirus A21 (CVA21) oncolytic virus immunotherapy in patients with advanced melanoma. *J Clin Oncol* 2015; 33(15_suppl): 9030
 61. Angelova AL, Witzens-Harig M, Galabov AS, Rommelaere J. The oncolytic virotherapy era in cancer management: prospects of applying H-1 parvovirus to treat blood and solid cancers. *Front Oncol* 2017; 7: 93
 62. Garant KA, Shmulevitz M, Pan L, Daigle RM, Ahn DG, Gujar SA, Lee PWK. Oncolytic reovirus induces intracellular redistribution of Ras to promote apoptosis and progeny virus release. *Oncogene* 2016; 35(6): 771–782
 63. Sborov DW, Nuovo GJ, Stiff A, Mace T, Lesinski GB, Benson DM Jr, Efebera YA, Rosko AE, Pichiorri F, Grever MR, Hofmeister CC. A phase I trial of single-agent reolysin in patients with relapsed multiple myeloma. *Clin Cancer Res* 2014; 20(23): 5946–5955
 64. Mahalingam D, Goel S, Aparo S, Patel Arora S, Noronha N, Tran H, Chakrabarty R, Selvaggi G, Gutierrez A, Coffey M, Nawrocki ST, Nuovo G, Mita MM. A phase II study of Pelareorep (REOLYSIN®) in combination with gemcitabine for patients with advanced pancreatic adenocarcinoma. *Cancers (Basel)* 2018; 10(6): 160
 65. Galanis E, Markovic SN, Suman VJ, Nuovo GJ, Vile RG, Kottke TJ, Nevala WK, Thompson MA, Lewis JE, Rumilla KM, Roulstone V, Harrington K, Linette GP, Maples WJ, Coffey M, Zwiebel J, Kendra K. Phase II trial of intravenous administration of Reolysin® (Reovirus Serotype-3-dearing Strain) in patients with metastatic melanoma. *Mol Ther* 2012; 20(10): 1998–2003
 66. Stiff A, Caserta E, Sborov DW, Nuovo GJ, Mo X, Schlotter SY, Canella A, Smith E, Badway J, Old M, Jaime-Ramirez AC, Yan P, Benson DM, Byrd JC, Baiocchi R, Kaur B, Hofmeister CC, Pichiorri F. Histone deacetylase inhibitors enhance the therapeutic potential of reovirus in multiple myeloma. *Mol Cancer Ther* 2016; 15(5):830–841
 67. Ramachandran M, Yu D, Dyczynski M, Baskaran S, Zhang L, Lulla A, Lulla V, Saul S, Nelander S, Dimberg A, Merits A, Leja-Jarblad J, Essand M. Safe and effective treatment of experimental neuroblastoma and glioblastoma using systemically delivered triple microRNA-detargeted oncolytic Semliki Forest Virus. *Clin Cancer Res* 2017; 23(6): 1519–1530
 68. Quetglas JI, Labiano S, Aznar MA, Bolaños E, Azpilikueta A, Rodriguez I, Casales E, Sánchez-Paulete AR, Segura V, Smerdou C, Melero I. Virotherapy with a Semliki Forest virus-based vector encoding IL12 synergizes with PD-1/PD-L1 blockade. *Cancer Immunol Res* 2015; 3(5): 449–454
 69. Huang PY, Guo JH, Hwang LH. Oncolytic Sindbis virus targets tumors defective in the interferon response and induces significant bystander antitumor immunity *in vivo*. *Mol Ther* 2012; 20(2): 298–305
 70. Lin Y, Zhang H, Liang J, Li K, Zhu W, Fu L, Wang F, Zheng X, Shi H, Wu S, Xiao X, Chen L, Tang L, Yan M, Yang X, Tan Y, Qiu P, Huang Y, Yin W, Su X, Hu H, Hu J, Yan G. Identification and characterization of alphavirus M1 as a selective oncolytic virus targeting ZAP-defective human cancers. *Proc Natl Acad Sci U S A* 2014; 111(42): E4504–E4512
 71. Hu C, Liu Y, Lin Y, Liang JK, Zhong WW, Li K, Huang WT, Wang DJ, Yan GM, Zhu WB, Qiu JG, Gao X. Intravenous injections of the oncolytic virus M1 as a novel therapy for muscle-invasive bladder cancer. *Cell Death Dis* 2018; 9(3): 274
 72. Liang J, Guo L, Li K, Xiao X, Zhu W, Zheng X, Hu J, Zhang H, Cai J, Yu Y, Tan Y, Li C, Liu X, Hu C, Liu Y, Qiu P, Su X, He S, Lin Y, Yan G. Inhibition of the mevalonate pathway enhances cancer cell oncolysis mediated by M1 virus. *Nat Commun* 2018; 9(1): 1524
 73. Zhang H, Lin Y, Li K, Liang J, Xiao X, Cai J, Tan Y, Xing F, Mai J, Li Y, Chen W, Sheng L, Gu J, Zhu W, Yin W, Qiu P, Su X, Lu B, Tian X, Liu J, Lu W, Dou Y, Huang Y, Hu B, Kang Z, Gao G, Mao Z, Cheng SY, Lu L, Bai XT, Gong S, Yan G, Hu J. Naturally existing oncolytic virus M1 is nonpathogenic for the nonhuman primates after multiple rounds of repeated intravenous injections. *Hum Gene Ther* 2016; 27(9): 700–711
 74. Zhang H, Li K, Lin Y, Xing F, Xiao X, Cai J, Zhu W, Liang J, Tan Y, Fu L, Wang F, Yin W, Lu B, Qiu P, Su X, Gong S, Bai X, Hu J, Yan G. Targeting VCP enhances anticancer activity of oncolytic virus M1 in hepatocellular carcinoma. *Sci Transl Med* 2017; 9(404): eaam7996
 75. Xiao X, Liang J, Huang C, Li K, Xing F, Zhu W, Lin Z, Xu W, Wu G, Zhang J, Lin X, Tan Y, Cai J, Hu J, Chen X, Huang Y, Qin Z, Qiu P, Su X, Chen L, Lin Y, Zhang H, Yan G. DNA-PK inhibition synergizes with oncolytic virus M1 by inhibiting antiviral response and potentiating DNA damage. *Nat Commun* 2018; 9(1): 4342
 76. Choi AH, O’Leary MP, Fong Y, Chen NG. From benchtop to bedside: a review of oncolytic virotherapy. *Biomedicines* 2016; 4(3): 18
 77. Maroun J, Muñoz-Alía M, Ammayappan A, Schulze A, Peng KW, Russell S. Designing and building oncolytic viruses. *Future Virol* 2017; 12(4):193–213
 78. Jhawar SR, Thandoni A, Bommareddy PK, Hassan S, Kohlhapp FJ, Goyal S, Schenkel JM, Silk AW, Zloza A. Oncolytic viruses—natural and genetically engineered cancer immunotherapies. *Front Oncol* 2017; 7: 202
 79. Bommareddy PK, Shettigar M, Kaufman HL. Integrating oncolytic viruses in combination cancer immunotherapy. *Nat Rev Immunol*

- 2018; 18(8): 498–513
80. Miest TS, Cattaneo R. New viruses for cancer therapy: meeting clinical needs. *Nat Rev Microbiol* 2014; 12(1): 23–34
 81. Stepanenko AA, Chekhonin VP. Tropism and transduction of oncolytic adenovirus 5 vectors in cancer therapy: focus on fiber chimerism and mosaicism, hexon and pIX. *Virus Res* 2018; 257: 40–51
 82. Foreman PM, Friedman GK, Cassady KA, Markert JM. Oncolytic virotherapy for the treatment of malignant glioma. *Neurotherapeutics* 2017; 14(2): 333–344
 83. Betancourt D, Ramos JC, Barber GN. Retargeting oncolytic vesicular stomatitis virus to human T-cell lymphotropic virus type 1-associated adult T-cell leukemia. *J Virol* 2015; 89(23): 11786–11800
 84. Leoni V, Vannini A, Gatta V, Rambaldi J, Sanapo M, Barboni C, Zaghini A, Nanni P, Lollini PL, Casiraghi C, Campadelli-Fiume G. A fully-virulent retargeted oncolytic HSV armed with IL-12 elicits local immunity and vaccine therapy towards distant tumors. *PLoS Pathog* 2018; 14(8): e1007209
 85. Menotti L, Cerretani A, Hengel H, Campadelli-Fiume G. Construction of a fully retargeted herpes simplex virus 1 recombinant capable of entering cells solely via human epidermal growth factor receptor 2. *J Virol* 2008; 82(20): 10153–10161
 86. Alessandrini F, Menotti L, Avitabile E, Appolloni I, Ceresa D, Marubbi D, Campadelli-Fiume G, Malatesta P. Eradication of glioblastoma by immuno-virotherapy with a retargeted oncolytic HSV in a preclinical model. *Oncogene* 2019; 38(23): 4467–4479
 87. Shibata T, Uchida H, Shiroyama T, Okubo Y, Suzuki T, Ikeda H, Yamaguchi M, Miyagawa Y, Fukuhara T, Cohen JB, Glorioso JC, Watabe T, Hamada H, Tahara H. Development of an oncolytic HSV vector fully retargeted specifically to cellular EpCAM for virus entry and cell-to-cell spread. *Gene Ther* 2016; 23(6): 479–488
 88. Uchida H, Marzulli M, Nakano K, Goins WF, Chan J, Hong CS, Mazzacurati L, Yoo JY, Haseley A, Nakashima H, Baek H, Kwon H, Kumagai I, Kuroki M, Kaur B, Chiocca EA, Grandi P, Cohen JB, Glorioso JC. Effective treatment of an orthotopic xenograft model of human glioblastoma using an EGFR-retargeted oncolytic herpes simplex virus. *Mol Ther* 2013; 21(3): 561–569
 89. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. *Cell* 2011; 144(5): 646–674
 90. Pikor LA, Bell JC, Diallo JS. Oncolytic viruses: exploiting cancer's deal with the devil. *Trends Cancer* 2015; 1(4): 266–277
 91. Kohlhapp FJ, Kaufman HL. Molecular pathways: mechanism of action for Talimogene Laherparepvec, a new oncolytic virus immunotherapy. *Clin Cancer Res* 2016; 22(5): 1048–1054
 92. Martínez-Vélez N, Xipell E, Vera B, Acanda de la Rocha A, Zalacain M, Marrodán L, Gonzalez-Huarriz M, Toledo G, Cascallo M, Alemany R, Patiño A, Alonso MM. The oncolytic adenovirus VCN-01 as therapeutic approach against pediatric osteosarcoma. *Clin Cancer Res* 2016; 22(9): 2217–2225
 93. Garant KA, Shmulevitz M, Pan L, Daigle RM, Ahn DG, Gujar SA, Lee PW. Oncolytic reovirus induces intracellular redistribution of Ras to promote apoptosis and progeny virus release. *Oncogene* 2016; 35(6): 771–782
 94. Lin WH, Yeh SH, Yang WJ, Yeh KH, Fujiwara T, Nii A, Chang SS, Chen PJ. Telomerase-specific oncolytic adenoviral therapy for orthotopic hepatocellular carcinoma in HBx transgenic mice. *Int J Cancer* 2013; 132(6): 1451–1462
 95. Li JM, Kao KC, Li LF, Yang TM, Wu CP, Horng YM, Jia WW, Yang CT. MicroRNA-145 regulates oncolytic herpes simplex virus-1 for selective killing of human non-small cell lung cancer cells. *Virology* 2013; 10(1): 241
 96. Fujiwara T, Shirakawa Y, Kagawa S. Telomerase-specific oncolytic virotherapy for human gastrointestinal cancer. *Expert Rev Anticancer Ther* 2011; 11(4): 525–532
 97. Harcastle J, Kurozumi K, Chiocca EA, Kaur B. Oncolytic viruses driven by tumor-specific promoters. *Curr Cancer Drug Targets* 2007; 7(2): 181–189
 98. Zhang W, Ge K, Zhao Q, Zhuang X, Deng Z, Liu L, Li J, Zhang Y, Dong Y, Zhang Y, Zhang S, Liu B. A novel oHSV-1 targeting telomerase reverse transcriptase-positive cancer cells via tumor-specific promoters regulating the expression of ICP4. *Oncotarget* 2015; 6(24): 20345–20355
 99. Taki M, Kagawa S, Nishizaki M, Mizuguchi H, Hayakawa T, Kyo S, Nagai K, Urata Y, Tanaka N, Fujiwara T. Enhanced oncolysis by a tropism-modified telomerase-specific replication-selective adenoviral agent OBP-405 ('Telomelysin-RGD'). *Oncogene* 2005; 24(19): 3130–3140
 100. Huang P, Kaku H, Chen J, Kashiwaka Y, Saika T, Nasu Y, Urata Y, Fujiwara T, Watanabe M, Kumon H. Potent antitumor effects of combined therapy with a telomerase-specific, replication-competent adenovirus (OBP-301) and IL-2 in a mouse model of renal cell carcinoma. *Cancer Gene Ther* 2010; 17(7): 484–491
 101. Shayestehpour M, Moghim S, Salimi V, Jalilvand S, Yavarian J, Romani B, Mokhtari-Azad T. Targeting human breast cancer cells by an oncolytic adenovirus using microRNA-targeting strategy. *Virus Res* 2017; 240: 207–214
 102. Leber MF, Baertsch MA, Anker SC, Henkel L, Singh HM, Bossow S, Engeland CE, Barkley R, Hoyler B, Albert J, Springfield C, Jäger D, von Kalle C, Ungerechts G. Enhanced control of oncolytic measles virus using microRNA target sites. *Mol Ther Oncolytics* 2018; 9: 30–40
 103. Leber MF, Bossow S, Leonard VH, Zaoui K, Grossardt C, Frenzke M, Miest T, Sawall S, Cattaneo R, von Kalle C, Ungerechts G. MicroRNA-sensitive oncolytic measles viruses for cancer-specific vector tropism. *Mol Ther* 2011; 19(6): 1097–1106
 104. McCart JA, Ward JM, Lee J, Hu Y, Alexander HR, Libutti SK, Moss B, Bartlett DL. Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. *Cancer Res* 2001; 61(24): 8751–8757
 105. Badrinath N, Heo J, Yoo SY. Viruses as nanomedicine for cancer. *Int J Nanomedicine* 2016; 11: 4835–4847
 106. Kanai R, Zaupa C, Sgubin D, Antoszczyk SJ, Martuza RL, Wakimoto H, Rabkin SD. Effect of γ 34.5 deletions on oncolytic herpes simplex virus activity in brain tumors. *J Virol* 2012; 86(8): 4420–4431
 107. McKie EA, MacLean AR, Lewis AD, Cruickshank G, Rampling R, Barnett SC, Kennedy PGE, Brown SM. Selective *in vitro* replication of herpes simplex virus type 1 (HSV-1) ICP34.5 null mutants in primary human CNS tumours—evaluation of a potentially effective clinical therapy. *Br J Cancer* 1996; 74(5): 745–752

108. Kim DH, Thorne SH. Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. *Nat Rev Cancer* 2009; 9(1): 64–71
109. Pease DF, Kratzke RA. Oncolytic viral therapy for mesothelioma. *Front Oncol* 2017; 7: 179
110. Jefferson A, Cadet VE, Hielscher A. The mechanisms of genetically modified vaccinia viruses for the treatment of cancer. *Crit Rev Oncol Hematol* 2015; 95(3): 407–416
111. Lauer UM, Schell M, Beil J, Berchtold S, Koppenhöfer U, Glatzle J, Königsrainer A, Möhle R, Nann D, Fend F, Pfannenbergs C, Bitzer M, Malek NP. Phase I study of oncolytic vaccinia virus GL-ONC1 in patients with peritoneal carcinomatosis. *Clin Cancer Res* 2018; 24(18): 4388–4398
112. Johnson DB, Puzanov I, Kelley MC. Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma. *Immunotherapy* 2015; 7(6): 611–619
113. Grigg C, Blake Z, Gartrell R, Sacher A, Taback B, Saenger Y. Talimogene laherparepvec (T-Vec) for the treatment of melanoma and other cancers. *Semin Oncol* 2016; 43(6): 638–646
114. Masoud SJ, Hu JB, Beasley GM, Stewart JH 4th, Mosca PJ. Efficacy of Talimogene Laherparepvec (T-VEC) therapy in patients with in-transit melanoma metastasis decreases with increasing lesion size. *Ann Surg Oncol* 2019; 26(13): 4633–4641
115. Zhu Z, Gorman MJ, McKenzie LD, Chai JN, Hubert CG, Prager BC, Fernandez E, Richner JM, Zhang R, Shan C, Tycksen E, Wang X, Shi PY, Diamond MS, Rich JN, Chheda MG. Zika virus has oncolytic activity against glioblastoma stem cells. *J Exp Med* 2017; 214(10): 2843–2857
116. Wikan N, Smith DR. Zika virus: history of a newly emerging arbovirus. *Lancet Infect Dis* 2016; 16(7): e119–e126
117. Yun SI, Lee YM. Zika virus: an emerging flavivirus. *J Microbiol* 2017; 55(3): 204–219
118. Shan C, Muruato AE, Nunes BTD, Luo H, Xie X, Medeiros DBA, Wakamiya M, Tesh RB, Barrett AD, Wang T, Weaver SC, Vasconcelos PFC, Rossi SL, Shi PY. A live-attenuated Zika virus vaccine candidate induces sterilizing immunity in mouse models. *Nat Med* 2017; 23(6): 763–767
119. Chen Q, Wu J, Ye Q, Ma F, Zhu Q, Wu Y, Shan C, Xie X, Li D, Zhan X, Li C, Li XF, Qin X, Zhao T, Wu H, Shi PY, Man J, Qin CF. Treatment of human glioblastoma with a live attenuated Zika virus vaccine candidate. *MBio* 2018; 9(5): e01683–18
120. Shan C, Xie X, Shi PY. Zika virus vaccine: progress and challenges. *Cell Host Microbe* 2018; 24(1): 12–17
121. Zeh HJ, Downs-Canner S, McCart JA, Guo ZS, Rao UN, Ramalingam L, Thorne SH, Jones HL, Kalinski P, Wieckowski E, O'Malley ME, Daneshmand M, Hu K, Bell JC, Hwang TH, Moon A, Breitbart CJ, Kim DH, Bartlett DL. First-in-man study of western reserve strain oncolytic vaccinia virus: safety, systemic spread, and antitumor activity. *Mol Ther* 2015; 23(1): 202–214
122. Breitbart CJ, De Silva NS, Falls TJ, Aladl U, Evgin L, Paterson J, Sun YY, Roy DG, Rintoul JL, Daneshmand M, Parato K, Stanford MM, Lichty BD, Fenster A, Kim D, Atkins H, Bell JC. Targeting tumor vasculature with an oncolytic virus. *Mol Ther* 2011; 19(5): 886–894
123. Breitbart CJ, Arulanandam R, De Silva N, Thorne SH, Patt R, Daneshmand M, Moon A, Ilkow C, Burke J, Hwang TH, Heo J, Cho M, Chen H, Angarita FA, Addison C, McCart JA, Bell JC, Kim DH. Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans. *Cancer Res* 2013; 73(4): 1265–1275
124. Hamid O, Hoffner B, Gasal E, Hong J, Carvajal RD. Oncolytic immunotherapy: unlocking the potential of viruses to help target cancer. *Cancer Immunol Immunother* 2017; 66(10): 1249–1264
125. Cody JJ, Hurst DR. Promising oncolytic agents for metastatic breast cancer treatment. *Oncolytic Virother* 2015; 4: 63–73
126. Pearl TM, Markert JM, Cassady KA, Ghonime MG. Oncolytic virus-based cytokine expression to improve immune activity in brain and solid tumors. *Mol Ther Oncolytics* 2019; 13: 14–21
127. Roth JC, Cassady KA, Cody JJ, Parker JN, Price KH, Coleman JM, Peggins JO, Noker PE, Powers NW, Grimes SD, Carroll SL, Gillespie GY, Whitley RJ, Markert JM. Evaluation of the safety and biodistribution of M032, an attenuated herpes simplex virus type 1 expressing hIL-12, after intracerebral administration to aotus nonhuman primates. *Hum Gene Ther Clin Dev* 2014; 25(1): 16–27
128. Patel DM, Foreman PM, Nabors LB, Riley KO, Gillespie GY, Markert JM. Design of a phase I clinical trial to evaluate M032, a genetically engineered HSV-1 expressing IL-12, in patients with recurrent/progressive glioblastoma multiforme, anaplastic astrocytoma, or gliosarcoma. *Hum Gene Ther Clin Dev* 2016; 27(2): 69–78
129. Wu Y, He J, An Y, Wang X, Liu Y, Yan S, Ye X, Qi J, Zhu S, Yu Q, Yin J, Li D, Wang W. Recombinant Newcastle disease virus (NDV/Anh-IL-2) expressing human IL-2 as a potential candidate for suppresses growth of hepatoma therapy. *J Pharmacol Sci* 2016; 132(1): 24–30
130. Hock K, Laengle J, Kuznetsova I, Egorov A, Hegedus B, Dome B, Wekerle T, Sacht M, Bergmann M. Oncolytic influenza A virus expressing interleukin-15 decreases tumor growth *in vivo*. *Surgery* 2017; 161(3): 735–746
131. Puskas J, Skrombolas D, Sedlacek A, Lord E, Sullivan M, Frelinger J. Development of an attenuated interleukin-2 fusion protein that can be activated by tumour-expressed proteases. *Immunology* 2011; 133(2): 206–220
132. Liu Z, Ge Y, Wang H, Ma C, Feist M, Ju S, Guo ZS, Bartlett DL. Modifying the cancer-immune set point using vaccinia virus expressing re-designed interleukin-2. *Nat Commun* 2018; 9(1): 4682
133. Autio K, Knuutila A, Kipar A, Pesonen S, Guse K, Parviainen S, Rajamäki M, Laitinen-Vapaavuori O, Vähä-Koskela M, Kanerva A, Hemminki A. Safety and biodistribution of a double-deleted oncolytic vaccinia virus encoding CD40 ligand in laboratory Beagles. *Mol Ther Oncolytics* 2014; 1: 14002
134. Huang JH, Zhang SN, Choi KJ, Choi IK, Kim JH, Lee MG, Kim H, Yun CO. Therapeutic and tumor-specific immunity induced by combination of dendritic cells and oncolytic adenovirus expressing IL-12 and 4-1BBL. *Mol Ther* 2010; 18(2): 264–274
135. Moran AE, Kovacsovics-Bankowski M, Weinberg AD. The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy. *Curr Opin Immunol* 2013; 25(2): 230–237
136. Eriksson E, Milenova I, Wenthe J, Stahle M, Leja-Jarblad J, Ullenhag G, Dimberg A, Moreno R, Alemany R, Loskog A. Shaping the tumor stroma and sparking immune activation by CD40 and 4-1BB signaling induced by an armed oncolytic virus. *Clin Cancer Res* 2017; 23(19): 5846–5857

137. Rosewell Shaw A, Suzuki M. Recent advances in oncolytic adenovirus therapies for cancer. *Curr Opin Virol* 2016; 21: 9–15
138. Navarro SA, Carrillo E, Griñán-Lisón C, Martín A, Perán M, Marchal JA, Boulaiz H. Cancer suicide gene therapy: a patent review. *Expert Opin Ther Pat* 2016; 26(9): 1095–1104
139. Zhu W, Zhang H, Shi Y, Song M, Zhu B, Wei L. Oncolytic adenovirus encoding tumor necrosis factor-related apoptosis inducing ligand (TRAIL) inhibits the growth and metastasis of triple-negative breast cancer. *Cancer Biol Ther* 2013; 14(11): 1016–1023
140. Hu J, Wang H, Gu J, Liu X, Zhou X. Trail armed oncolytic poxvirus suppresses lung cancer cell by inducing apoptosis. *Acta Biochim Biophys Sin (Shanghai)* 2018; 50(10): 1018–1027
141. Chen S, Li YQ, Yin XZ, Li SZ, Zhu YL, Fan YY, Li WJ, Cui YL, Zhao J, Li X, Zhang QG, Jin NY. Recombinant adenoviruses expressing apoptin suppress the growth of MCF7 breast cancer cells and affect cell autophagy. *Oncol Rep* 2019; 41(5): 2818–2832
142. Zhou W, Dai S, Zhu H, Song Z, Cai Y, Lee JB, Li Z, Hu X, Fang B, He C, Huang X. Telomerase-specific oncolytic adenovirus expressing TRAIL suppresses peritoneal dissemination of gastric cancer. *Gene Ther* 2017; 24(4): 199–207
143. Liu L, Wu W, Zhu G, Liu L, Guan G, Li X, Jin N, Chi B. Therapeutic efficacy of an hTERT promoter-driven oncolytic adenovirus that expresses apoptin in gastric carcinoma. *Int J Mol Med* 2012; 30(4): 747–754
144. Schepelmann S, Springer CJ. Viral vectors for gene-directed enzyme prodrug therapy. *Curr Gene Ther* 2006; 6(6): 647–670
145. Zhang J, Kale V, Chen M. Gene-directed enzyme prodrug therapy. *AAPS J* 2015; 17(1): 102–110
146. Chalikonda S, Kivlen MH, O'Malley ME, Eric Dong XD, McCart JA, Gorry MC, Yin XY, Brown CK, Zeh HJ 3rd, Guo ZS, Bartlett DL. Oncolytic virotherapy for ovarian carcinomatosis using a replication-selective vaccinia virus armed with a yeast cytosine deaminase gene. *Cancer Gene Ther* 2008; 15(2): 115–125
147. Dias JD, Liikanen I, Guse K, Foloppe J, Sloniecka M, Diaconu I, Rantanen V, Eriksson M, Hakkarainen T, Lusky M, Erbs P, Escutenaire S, Kanerva A, Pesonen S, Cerullo V, Hemminki A. Targeted chemotherapy for head and neck cancer with a chimeric oncolytic adenovirus coding for bifunctional suicide protein FCU1. *Clin Cancer Res* 2010; 16(9): 2540–2549
148. Foloppe J, Kempf J, Futin N, Kintz J, Cordier P, Pichon C, Findeli A, Vorburger F, Quemeneur E, Erbs P. The enhanced tumor specificity of TG6002, an armed oncolytic vaccinia virus deleted in two genes involved in nucleotide metabolism. *Mol Ther Oncolytics* 2019; 14: 1–14
149. Erbs P, Regulier E, Kintz J, Leroy P, Poitevin Y, Exinger F, Jund R, Mehtali M. *In vivo* cancer gene therapy by adenovirus-mediated transfer of a bifunctional yeast cytosine deaminase/uracil phosphoribosyltransferase fusion gene. *Cancer Res* 2000; 60(14): 3813–3822
150. Smith E, Breznik J, Lichty BD. Strategies to enhance viral penetration of solid tumors. *Hum Gene Ther* 2011; 22(9): 1053–1060
151. Kim JH, Lee YS, Kim H, Huang JH, Yoon AR, Yun CO. Relaxin expression from tumor-targeting adenoviruses and its intratumoral spread, apoptosis induction, and efficacy. *J Natl Cancer Inst* 2006; 98(20): 1482–1493
152. Schäfer S, Weibel S, Donat U, Zhang Q, Aguilar RJ, Chen NG, Szalay AA. Vaccinia virus-mediated intra-tumoral expression of matrix metalloproteinase 9 enhances oncolysis of PC-3 xenograft tumors. *BMC Cancer* 2012; 12(1): 366
153. Dmitrieva N, Yu L, Viapiano M, Cripe TP, Chiocca EA, Glorioso JC, Kaur B. Chondroitinase ABC I-mediated enhancement of oncolytic virus spread and antitumor efficacy. *Clin Cancer Res* 2011; 17(6): 1362–1372
154. Guedan S, Rojas JJ, Gros A, Mercade E, Cascallo M, Alemany R. Hyaluronidase expression by an oncolytic adenovirus enhances its intratumoral spread and suppresses tumor growth. *Mol Ther* 2010; 18(7): 1275–1283
155. Rodríguez-García A, Giménez-Alejandro M, Rojas JJ, Moreno R, Bazan-Peregrino M, Cascalló M, Alemany R. Safety and efficacy of VCN-01, an oncolytic adenovirus combining fiber HSG-binding domain replacement with RGD and hyaluronidase expression. *Clin Cancer Res* 2015; 21(6): 1406–1418
156. Pascual-Pasto G, Bazan-Peregrino M, Olaciregui NG, Restrepo-Perdomo CA, Mato-Berciano A, Ottaviani D, Weber K, Correa G, Paco S, Vila-Ubach M, Cuadrado-Vilanova M, Castillo-Ecija H, Botteri G, Garcia-Gerique L, Moreno-Gilbert H, Gimenez-Alejandro M, Alonso-Lopez P, Farrera-Sal M, Torres-Manjon S, Ramos-Lozano D, Moreno R, Aerts I, Doz F, Cassoux N, Chapeaublanc E, Torredadell M, Roldan M, König A, Suñol M, Claverol J, Lavarino C, Carmen de T, Fu L, Radvanyi F, Munier FL, Catalá-Mora J, Mora J, Alemany R, Cascalló M, Chantada GL, Carcaboso AM. Therapeutic targeting of the RB1 pathway in retinoblastoma with the oncolytic adenovirus VCN-01. *Sci Transl Med* 2019; 11(476): eaat9321
157. Viillard C, Larrivé B. Tumor angiogenesis and vascular normalization: alternative therapeutic targets. *Angiogenesis* 2017; 20(4): 409–426
158. Siveen KS, Prabhu K, Krishnankutty R, Kuttikrishnan S, Tsakou M, Alali FQ, Dermime S, Mohammad RM, Uddin S. Vascular endothelial growth factor (VEGF) signaling in tumour vascularization: potential and challenges. *Curr Vasc Pharmacol* 2017; 15(4): 339–351
159. Frentzen A, Yu YA, Chen N, Zhang Q, Weibel S, Raab V, Szalay AA. Anti-VEGF single-chain antibody GLAF-1 encoded by oncolytic vaccinia virus significantly enhances antitumor therapy. *Proc Natl Acad Sci USA* 2009; 106(31): 12915–12920
160. Goodwin JM, Schmitt AD, McGinn CM, Fuchs BC, Kuruppu D, Tanabe KK, Lanuti M. Angiogenesis inhibition using an oncolytic herpes simplex virus expressing endostatin in a murine lung cancer model. *Cancer Invest* 2012; 30(3): 243–250
161. Hutzen B, Bid HK, Houghton PJ, Pierson CR, Powell K, Bratasz A, Raffel C, Studebaker AW. Treatment of medulloblastoma with oncolytic measles viruses expressing the angiogenesis inhibitors endostatin and angiostatin. *BMC Cancer* 2014; 14(1): 206
162. Tsuji T, Nakamori M, Iwahashi M, Nakamura M, Ojima T, Iida T, Katsuda M, Hayata K, Ino Y, Todo T, Yamaue H. An armed oncolytic herpes simplex virus expressing thrombospondin-1 has an enhanced *in vivo* antitumor effect against human gastric cancer. *Int J Cancer* 2013; 132(2): 485–494
163. Miller A, Russell SJ. The use of the NIS reporter gene for optimizing oncolytic virotherapy. *Expert Opin Biol Ther* 2016; 16(1): 15–32

164. Haddad D. Genetically engineered vaccinia viruses as agents for cancer treatment, imaging, and transgene delivery. *Front Oncol* 2017; 7: 96
165. Domingo-Musibay E, Allen C, Kurokawa C, Hardcastle JJ, Aderca I, Msaouel P, Bansal A, Jiang H, DeGrado TR, Galanis E. Measles Edmonston vaccine strain derivatives have potent oncolytic activity against osteosarcoma. *Cancer Gene Ther* 2014; 21(11): 483–490
166. Jiang K, Song C, Kong L, Hu L, Lin G, Ye T, Yao G, Wang Y, Chen H, Cheng W, Barr MP, Liu Q, Zhang G, Ding C, Meng S. Recombinant oncolytic Newcastle disease virus displays antitumor activities in anaplastic thyroid cancer cells. *BMC Cancer* 2018; 18(1): 746
167. Aref S, Bailey K, Fielding A. Measles to the rescue: a review of oncolytic measles virus. *Viruses* 2016; 8(10): 294
168. Peng KW, Fecteau S, Wegman T, O’Kane D, Russell SJ. Non-invasive *in vivo* monitoring of trackable viruses expressing soluble marker peptides. *Nat Med* 2002; 8(5): 527–531
169. Robinson S, Galanis E. Potential and clinical translation of oncolytic measles viruses. *Expert Opin Biol Ther* 2017; 17(3): 353–363
170. Johnson DB, Puzanov I, Kelley MC. Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma. *Immunotherapy* 2015; 7(6): 611–619
171. Bell J, McFadden G. Viruses for tumor therapy. *Cell Host Microbe* 2014; 15(3): 260–265
172. Andtbacka RH, Agarwala SS, Ollila DW, Hallmeyer S, Milhem M, Amatruda T, Nemunaitis JJ, Harrington KJ, Chen L, Shilkrut M, Ross M, Kaufman HL. Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma. *Head Neck* 2016; 38(12): 1752–1758
173. Eissa IR, Naoe Y, Bustos-Villalobos I, Ichinose T, Tanaka M, Zhiwen W, Mukoyama N, Morimoto T, Miyajima N, Hitoki H, Sumigama S, Aleksic B, Kodera Y, Kasuya H. Genomic signature of the natural oncolytic herpes simplex virus HF10 and its therapeutic role in preclinical and clinical trials. *Front Oncol* 2017; 7: 149
174. Martínez-Vélez N, García-Moure M, Marigil M, González-Huarriz M, Puigdelloses M, Gallego Pérez-Larraya J, Zalacain M, Marrodán L, Varela-Guruceaga M, Laspidea V, Aristu JJ, Ramos LI, Tejada-Solis S, Díez-Valle R, Jones C, Mackay A, Martínez-Climent JA, García-Barchino MJ, Raabe E, Monje M, Becher OJ, Junier MP, El-Habr EA, Chneiweiss H, Aldave G, Jiang H, Fueyo J, Patiño-García A, Gomez-Manzano C, Alonso MM. The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models. *Nat Commun* 2019; 10(1): 2235
175. Nakajima O, Ichimaru D, Urata Y, Fujiwara T, Horibe T, Kohno M, Kawakami K. Use of telomelysin (OBP-301) in mouse xenografts of human head and neck cancer. *Oncol Rep* 2009; 22(5): 1039–1043
176. Breitbach CJ, Parato K, Burke J, Hwang TH, Bell JC, Kirn DH. Pexa-Vec double agent engineered vaccinia: oncolytic and active immunotherapeutic. *Curr Opin Virol* 2015; 13: 49–54
177. Singh P, Pal SK, Alex A, Agarwal N. Development of PROSTVAC immunotherapy in prostate cancer. *Future Oncol* 2015; 11(15): 2137–2148
178. Felt SA, Grdzlishvili VZ. Recent advances in vesicular stomatitis virus-based oncolytic virotherapy: a 5-year update. *J Gen Virol* 2017; 98(12): 2895–2911
179. Brown MC, Gromeier M. Cytotoxic and immunogenic mechanisms of recombinant oncolytic poliovirus. *Curr Opin Virol* 2015; 13: 81–85
180. Desjardins A, Gromeier M, Herndon JE 2nd, Beaubier N, Bolognesi DP, Friedman AH, Friedman HS, McSherry F, Muscat AM, Nair S, Peters KB, Randazzo D, Sampson JH, Vlahovic G, Harrison WT, McLendon RE, Ashley D, Bigner DD. Recurrent glioblastoma treated with recombinant poliovirus. *N Engl J Med* 2018; 379(2): 150–161
181. Atherton MJ, Stephenson KB, Nikota JK, Hu QN, Nguyen A, Wan Y, Lichty BD. Preclinical development of peptide vaccination combined with oncolytic MG1-E6E7 for HPV-associated cancer. *Vaccine* 2018; 36(16): 2181–2192
182. Gong J, Sachdev E, Mita AC, Mita MM. Clinical development of reovirus for cancer therapy: an oncolytic virus with immune-mediated antitumor activity. *World J Methodol* 2016; 6(1):25–42
183. Geletneky K, Nüesch JPF, Angelova A, Kiprianova I, Rommelaere J. Double-faceted mechanism of parvoviral oncosuppression. *Curr Opin Virol* 2015; 13: 17–24
184. Hajda J, Lehmann M, Krebs O, Kieser M, Geletneky K, Jäger D, Dahm M, Huber B, Schöning T, Sedlacek O, Stenzinger A, Halama N, Daniel V, Leuchs B, Angelova A, Rommelaere J, Engeland CE, Springfield C, Ungerechts G. A non-controlled, single arm, open label, phase II study of intravenous and intratumoral administration of ParvOryx in patients with metastatic, inoperable pancreatic cancer: ParvOryx02 protocol. *BMC Cancer* 2017; 17(1): 576
185. Lorence RM, Roberts MS, O’Neil JD, Groene WS, Miller JA, Mueller SN, Bamat MK. Phase 1 clinical experience using intravenous administration of PV701, an oncolytic Newcastle disease virus. *Curr Cancer Drug Targets* 2007; 7(2): 157–167
186. Bauzon M, Hermiston T. Armed therapeutic viruses — a disruptive therapy on the horizon of cancer immunotherapy. *Front Immunol* 2014; 5: 74
187. Nguyen A, Ho L, Wan Y. Chemotherapy and oncolytic virotherapy: advanced tactics in the war against cancer. *Front Oncol* 2014; 4: 145
188. Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. *Cancer Cell* 2015; 27(4): 450–461
189. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. *Nat Rev Cancer* 2012; 12(4): 252–264
190. Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, Dawson N, O’Donnell PH, Balmanoukian A, Loriot Y, Srinivas S, Retz MM, Grivas P, Joseph RW, Galsky MD, Fleming MT, Petrylak DP, Perez-Gracia JL, Burris HA, Castellano D, Canil C, Bellmunt J, Bajorin D, Nickles D, Bourgon R, Frampton GM, Cui N, Mariathasan S, Abidoye O, Fine GD, Dreicer R. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. *Lancet* 2016; 387(10031): 1909–1920

191. Alsaab HO, Sau S, Alzhrani R, Tatiparti K, Bhise K, Kashaw SK, Iyer AK. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. *Front Pharmacol* 2017; 8: 561
192. Wang Q, Wu X. Primary and acquired resistance to PD-1/PD-L1 blockade in cancer treatment. *Int Immunopharmacol* 2017; 46: 210–219
193. Kalbasi A, Ribas A. Tumour-intrinsic resistance to immune checkpoint blockade. *Nat Rev Immunol* 2020; 20(1): 25–39
194. Liu Z, Ravindranathan R, Kalinski P, Guo ZS, Bartlett DL. Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy. *Nat Commun* 2017; 8(1): 14754
195. Chen CY, Wang PY, Hutzen B, Sprague L, Swain HM, Love JK, Stanek JR, Boon L, Conner J, Cripe TP. Cooperation of oncolytic herpes virotherapy and PD-1 blockade in murine rhabdomyosarcoma models. *Sci Rep* 2017; 7(1): 2396
196. Hardcastle J, Mills L, Malo CS, Jin F, Kurokawa C, Geekiyana H, Schroeder M, Sarkaria J, Johnson AJ, Galanis E. Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment. *Neuro Oncol* 2017; 19(4): 493–502
197. Shen W, Patnaik MM, Ruiz A, Russell SJ, Peng KW. Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia. *Blood* 2016; 127(11): 1449–1458
198. Saha D, Martuza RL, Rabkin SD. Macrophage polarization contributes to glioblastoma eradication by combination immunovirotherapy and immune checkpoint blockade. *Cancer Cell* 2017; 32(2): 253–267.e5
199. Fend L, Yamazaki T, Remy C, Fahrner C, Gantzer M, Nourtier V, Prévillé X, Quéméneur E, Kepp O, Adam J, Marabelle A, Pitt JM, Kroemer G, Zitvogel L. Immune checkpoint blockade, immunogenic chemotherapy or IFN- α blockade boost the local and abscopal effects of oncolytic virotherapy. *Cancer Res* 2017; 77(15): 4146–4157
200. Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RHI, Michielin O, Olszanski AJ, Malvey J, Cebon J, Fernandez E, Kirkwood JM, Gajewski TF, Chen L, Gorski KS, Anderson AA, Diede SJ, Lassman ME, Gansert J, Hodi FS, Long GV. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. *Cell* 2017; 170(6): 1109–1119.e10
201. Sun L, Funchain P, Song JM, Rayman P, Tannenbaum C, Ko J, Mcnamara M, Marcela Diaz-Montero C, Gastman B. Talimogene Laherparepvec combined with anti-PD-1 based immunotherapy for unresectable stage III-IV melanoma: a case series. *J Immunother Cancer* 2018; 6(1): 36
202. Puzanov I, Milhem MM, Minor D, Hamid O, Li A, Chen L, Chastain M, Gorski KS, Anderson A, Chou J, Kaufman HL, Andtbacka RH. Talimogene Laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB-IV melanoma. *J Clin Oncol* 2016; 34(22): 2619–2626
203. Chesney J, Puzanov I, Collichio F, Singh P, Milhem MM, Glaspy J, Hamid O, Ross M, Friedlander P, Garbe C, Logan TF, Hauschild A, Lebbé C, Chen L, Kim JJ, Gansert J, Andtbacka RHI, Kaufman HL. Randomized, open-label phase II study evaluating the efficacy and safety of Talimogene Laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma. *J Clin Oncol* 2018; 36(17): 1658–1667
204. Wing A, Fajardo CA, Posey AD, Shaw C, Da T, Young RM, Alemany R, June CH, Guedan S. Improving CART-cell therapy of solid tumors with oncolytic virus-driven production of a bispecific T-cell engager. *Cancer Immunol Res* 2018; 6(5): 605–616
205. Watanabe K, Luo Y, Da T, Guedan S, Ruella M, Scholler J, Keith B, Young RM, Engels B, Sorsa S, Siurala M, Havunen R, Tähtinen S, Hemminki A, June CH. Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses. *JCI Insight* 2018; 3(7): e99573
206. Nishio N, Diaconu I, Liu H, Cerullo V, Caruana I, Hoyos V, Bouchier-Hayes L, Savoldo B, Dotti G. Armed oncolytic virus enhances immune functions of chimeric antigen receptor-modified T cells in solid tumors. *Cancer Res* 2014; 74(18): 5195–5205
207. Rosewell Shaw A, Porter CE, Watanabe N, Tanoue K, Sikora A, Gottschalk S, Brenner MK, Suzuki M. Adenovirotherapy delivering cytokine and checkpoint inhibitor augments CAR T cells against metastatic head and neck cancer. *Mol Ther* 2017; 25(11): 2440–2451
208. Tanoue K, Rosewell Shaw A, Watanabe N, Porter C, Rana B, Gottschalk S, Brenner M, Suzuki M. Armed oncolytic adenovirus-expressing PD-L1 mini-body enhances antitumor effects of chimeric antigen receptor T cells in solid tumors. *Cancer Res* 2017; 77(8): 2040–2051
209. Pento JT. Monoclonal antibodies for the treatment of cancer. *Anticancer Res* 2017; 37(11): 5935–5939
210. [No authors listed] Cemiplimab approved for treatment of CSCC. *Cancer Discov* 2018; 8(12): OF2
211. Syed YY. Durvalumab: first global approval. *Drugs* 2017; 77(12): 1369–1376
212. Tumeq PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V, West AN, Carmona M, Kivork C, Seja E, Cherry G, Gutierrez AJ, Grogan TR, Mateus C, Tomasic G, Glaspy JA, Emerson RO, Robins H, Pierce RH, Elashoff DA, Robert C, Ribas A. PD-1 blockade induces responses by inhibiting adaptive immune resistance. *Nature* 2014; 515(7528): 568–571
213. Taipale K, Liikanen I, Juhila J, Karioja-Kallio A, Oksanen M, Turkki R, Linder N, Lundin J, Ristimäki A, Kanerva A, Koski A, Joensuu T, Vähä-Koskela M, Hemminki A. T-cell subsets in peripheral blood and tumors of patients treated with oncolytic adenoviruses. *Mol Ther* 2015; 23(5): 964–973
214. Pesonen S, Diaconu I, Kangasniemi L, Ranki T, Kanerva A, Pesonen SK, Gerdemann U, Leen AM, Kairemo K, Oksanen M, Haavisto E, Holm SL, Karioja-Kallio A, Kauppinen S, Partanen KP, Laasonen L, Joensuu T, Alanko T, Cerullo V, Hemminki A. Oncolytic immunotherapy of advanced solid tumors with a CD40L-expressing replicating adenovirus: assessment of safety and immunologic responses in patients. *Cancer Res* 2012; 72(7): 1621–1631
215. Letendre P, Monga V, Milhem M, Zakharia Y. Ipilimumab: from preclinical development to future clinical perspectives in melanoma. *Future Oncol* 2017; 13(7): 625–636
216. Pagel JM, West HJ. Chimeric antigen receptor (CAR) T-cell therapy. *JAMA Oncol* 2017; 3(11): 1595

217. Anderson JK, Mehta A. A review of chimeric antigen receptor T-cells in lymphoma. *Expert Rev Hematol* 2019; 12(7): 551–561
218. Mikkilineni L, Kochenderfer JN. Chimeric antigen receptor T-cell therapies for multiple myeloma. *Blood* 2017; 130(24): 2594–2602
219. Jackson HJ, Rafiq S, Brentjens RJ. Driving CAR T-cells forward. *Nat Rev Clin Oncol* 2016; 13(6): 370–383
220. Long KB, Young RM, Boesteanu AC, Davis MM, Melenhorst JJ, Lacey SF, DeGaramo DA, Levine BL, Fraietta JA. CAR T cell therapy of non-hematopoietic malignancies: detours on the road to clinical success. *Front Immunol* 2018; 9: 2740
221. Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, Bartido S, Stefanski J, Taylor C, Olszewska M, Borquez-Ojeda O, Qu J, Wasielewska T, He Q, Bernal Y, Rijo IV, Hedvat C, Kobos R, Curran K, Steinherz P, Jurcic J, Rosenblatt T, Maslak P, Frattini M, Sadelain M. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. *Sci Transl Med* 2013; 5(177): 177ra38
222. Li J, Li W, Huang K, Zhang Y, Kupfer G, Zhao Q. Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward. *J Hematol Oncol* 2018; 11(1): 22
223. Gajewski TF, Woo SR, Zha Y, Spaapen R, Zheng Y, Corrales L, Spranger S. Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. *Curr Opin Immunol* 2013; 25(2): 268–276
224. Lavin Y, Kobayashi S, Leader A, Amir ED, Elefant N, Bigenwald C, Remark R, Sweeney R, Becker CD, Levine JH, Meinhof K, Chow A, Kim-Shulze S, Wolf A, Medaglia C, Li H, Rytlewski JA, Emerson RO, Solovyov A, Greenbaum BD, Sanders C, Vignali M, Beasley MB, Flores R, Gnjatic S, Pe'er D, Rahman A, Amit I, Merad M. Innate immune landscape in early lung adenocarcinoma by paired single-cell analyses. *Cell* 2017; 169(4): 750–765.e17
225. Salter AI, Riddell SR. A BiTE from cancer's intracellular menu. *Nat Biotechnol* 2015; 33(10): 1040–1041
226. Huehls AM, Coupet TA, Sentman CL. Bispecific T-cell engagers for cancer immunotherapy. *Immunol Cell Biol* 2015; 93(3): 290–296
227. Stiegmaier J, Benjamin J, Nagorsen D. Utilizing the BiTE (bispecific T-cell engager) platform for immunotherapy of cancer. *Expert Opin Biol Ther* 2015; 15(8): 1093–1099
228. Scott EM, Duffy MR, Freedman JD, Fisher KD, Seymour LW. Solid tumor immunotherapy with T cell engager-armed oncolytic viruses. *Macromol Biosci* 2018; 18(1): 1700187
229. Cheung A, Bax HJ, Josephs DH, Ilieva KM, Pellizzari G, Opzoomer J, Bloomfield J, Fittall M, Grigoriadis A, Figini M, Canevari S, Spicer JF, Tutt AN, Karagiannis SN. Targeting folate receptor alpha for cancer treatment. *Oncotarget* 2016; 7(32): 52553–52574
230. Zolov SN, Rietberg SP, Bonifant CL. Programmed cell death protein 1 activation preferentially inhibits CD28.CAR-T cells. *Cytotherapy* 2018; 20(10): 1259–1266
231. Cherkassky L, Morello A, Villena-Vargas J, Feng Y, Dimitrov DS, Jones DR, Sadelain M, Adusumilli PS. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. *J Clin Invest* 2016; 126(8): 3130–3144
232. Mahoney KM, Rennert PD, Freeman GJ. Combination cancer immunotherapy and new immunomodulatory targets. *Nat Rev Drug Discov* 2015; 14(8): 561–584
233. Serganova I, Moroz E, Cohen I, Moroz M, Mane M, Zurita J, Shenker L, Ponomarev V, Blasberg R. Enhancement of PSMA-directed CAR adoptive immunotherapy by PD-1/PD-L1 blockade. *Mol Ther Oncolytics* 2017; 4: 41–54
234. Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. *N Engl J Med* 2018; 378(2): 158–168
235. Svane IM, Verdegaal EM. Achievements and challenges of adoptive T cell therapy with tumor-infiltrating or blood-derived lymphocytes for metastatic melanoma: what is needed to achieve standard of care? *Cancer Immunol Immunother* 2014; 63(10): 1081–1091
236. Besser MJ, Shapira-Frommer R, Itzhaki O, Treves AJ, Zippel DB, Levy D, Kubi A, Shoshani N, Zikich D, Ohayon Y, Ohayon D, Shalmon B, Markel G, Yerushalmi R, Apter S, Ben-Nun A, Ben-Ami E, Shimoni A, Nagler A, Schachter J. Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies. *Clin Cancer Res* 2013; 19(17): 4792–4800
237. Santos JM, Havunen R, Siurala M, Cervera-Carrascon V, Tähtinen S, Sorsa S, Anttila M, Karell P, Kanerva A, Hemminki A. Adenoviral production of interleukin-2 at the tumor site removes the need for systemic preconditioning in adoptive cell therapy. *Int J Cancer* 2017; 141(7): 1458–1468
238. Hamano S, Mori Y, Aoyama M, Kataoka H, Tanaka M, Ebi M, Kubota E, Mizoshita T, Tanida S, Johnston RN, Asai K, Joh T. Oncolytic reovirus combined with trastuzumab enhances antitumor efficacy through TRAIL signaling in human HER2-positive gastric cancer cells. *Cancer Lett* 2015; 356(2 Pt B): 846–854
239. Tan G, Kasuya H, Sahin TT, Yamamura K, Wu Z, Koide Y, Hotta Y, Shikano T, Yamada S, Kanzaki A, Fujii T, Sugimoto H, Nomoto S, Nishikawa Y, Tanaka M, Tsurumaru N, Kuwahara T, Fukuda S, Ichinose T, Kikumori T, Takeda S, Nakao A, Koderia Y. Combination therapy of oncolytic herpes simplex virus HF10 and bevacizumab against experimental model of human breast carcinoma xenograft. *Int J Cancer* 2015; 136(7): 1718–1730
240. Bommareddy PK, Aspromonte S, Zloza A, Rabkin SD, Kaufman HL. MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation. *Sci Transl Med* 2018; 10(471): eaau0417
241. Abdullahi S, Jäkel M, Behrend SJ, Steiger K, Topping G, Krabbe T, Colombo A, Sandig V, Schiergens TS, Thasler WE, Werner J, Lichtenthaler SF, Schmid RM, Ebert O, Altomonte J. A novel chimeric oncolytic virus vector for improved safety and efficacy as a platform for the treatment of hepatocellular carcinoma. *J Virol* 2018; 92(23): e01386-18